 
 
 
 
Protocol I8H-MC -BDCP(d)  
 
 
A Phase 2, Randomized, Parallel, Open -Label Comparator -Controlled 
Trial to  Evaluate the Safety and Efficacy of LY3209590 in Study 
Participants with Type 1 Diabetes Mellitus Previously Treated with 
Multiple Daily Injection Therapy.  
 
 
[STUDY_ID_REMOVED]    
  Approval Date: 28-Oct -2020 
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 1Title P a ge 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of L Y 3 2 0 9 5 9 0 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s .
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al 
i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y 
p u bli c r el e a s e.  I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e 
r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Pr ot oc ol Title: A P hase 2, Ra n d o mize d, Parallel, O pe n -La bel  C o m p ar at or -C o nt r olle d Tri al t o 
E val uate t he Safet y a n d Efficac y of L Y 3 2 0 9 5 9 0 i n St u d y  P arti ci pa nts wi t h  T y pe 
1 Dia betes Mellit us Pre vi o usl y Treate d wit h M ult i ple Dail y I nject i o n T hera p y 
Pr ot oc ol N u m ber: I 8 H- M C -B D C P 
A me n d me nt N u m ber: d
C o m p o u n d :L Y 3 2 0 9 5 9 0 
St u d y P h ase: P hase 2
S h ort Title: A St u d y  of  L Y 3 2 0 9 5 9 0 i n Partici pa nts wit h T y pe 1Di a betes Mellit us 
S p o ns or N a me: El i Lill y a n d C o m pa n y 
Le g al Re gistere d A d dress: I n di a na p olis, I n dia na U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber(s) 
I N D: 1 2 9 3 9 0 
E u dra C T:  2 0 1 9- 0 0 3 5 8 9- 4 1 
A p pr o v al D ate: Pr ot oc ol A me n d me nt (d) El ectr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n date 
pr o vi de d bel o w. 
Lill y Me dic al N a me a n d C o nt act I nf or m ati o n will be pr o vi de d se p ar atel y .
A p pr o v al D at e: 2 8- O ct- 2 0 2 0 G M T 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 2Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 11-Dec -2019
Amendment (a) 08-Apr -2020
Amendment (b) 12-Jun-2020
Amendment (c) 14-Aug -2020
Amendment [d] 
This amendment is consi dered substant ialbased on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The amendment provides informat ion to reflect terminat ion of the invest igational medical device 
study  arm evaluat ing the individualized accruing data algorithm (Algorithm 2) invest igational 
device in the Phase 2 Study 18H -MC-BDCP (BDCP).  Study  BDCP will continue to evaluat e
dosing regimens of invest igational medicinal product LY3209590, a long -acting insulin receptor 
agonist that is being developed as a basal insulin administered once -weekly for trea tment of type 
1 diabetes mellitus (T1DM) .  Study  BDCP is evaluating T1DM participants previously  treated 
with multiple daily inject ions (MDI) therapy  in paper algorithm (Algorithm 1).  Insulin degludec 
is an unblinded act ive co mparator in this study. 
Lilly is terminat ing the Algorithm 2 study  arm due to the extent of data entry  errors generated by  
patients and the impact these errors have on dosing recommendations from the invest igational 
device Algorithm 2. These errors (missing, unchecked, or uncorre cted by  site verificat ion) 
provi de less than com plete data set inputs that are submitted by  the invest igator into the 
Algori thm 2 dosing calculation.  The limited data set inputs have revealed shortcomings in the 
dosing calculat ion confounding factors for the limited number of Algorithm 2 dosing 
recommendat ions observed fro m a limi ted number of sites and participants during the early  
enrollment phase.  In some cases, had the investigator not applied clinical judgement to override 
the recommended dose, a ser ious adverse consequence on patient health and/or safet y associ ated 
with the device may  have resul ted. 
The extent of the invest igator Algorithm 2 recommended dose overrides experienced to date 
have confounded evaluat ion of Algorithm 2’s effectiveness.  Li lly recognized that the pl anned 
expansio n to i nclude all sites participat ing in the United States would increase both the number 
of parti cipants exposed to the investigational device Algorithm 2 and the number of invest igators 
provi ding oversite of the Alg orithm 2 dosing recommendat ions. This amendment reflects th e 
prevent ive act ion to terminate the Algorithm 2 investigational device trial arm of Study BDCP 
due to challenges associated with the abilit y to evaluate the effect iveness of Algorithm 2, to 
preve nt potential pat ient safet y issues and avoid a delay in the study .
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 3Section # and Name Description of Change Brief Rationale
Throughout the document Removal of language related to 
Algorithm 2Alignment of protocol for removal of 
Algorithm 2
Section 1.1. Synopsis
Section 6.1. Study 
Intervention(s) Administered
Section 9.2. Sample Size 
Determination 
Section 10.10. Appendix 10:
Changes to S tudy Procedures 
due to the COVID -19 
Pandemic or Natural DisastersChange in number of 
participants ,randomization 
ratio,and distribution by 
countryBased on the removal of Algorithm 2, the 
participant number was updated and 
randomization variation by country is no 
longer applicable .
Section 1.3. Schedule of 
ActivitiesAddition of language for 
footnote dClarification tha t a triplicate ECG for insulin 
degludec is only required one time.
Addition of language for
footnote eClarification of the collection of 2 PK 
samples isfor LY3209590. 
Removal of CGM data 
download atVisit 16Rem oved CGM data download at Study Visit 
16 as this is a phone visit and download is 
not possible. 
Section 6.1. Study 
Interventions(s) AdministeredAddition of language for 
participants transitioning from 
Algorithm 2Clarification for participants in Alg orithm 2 
to proceed with study procedures for those 
treated with LY3209590. 
Section 8.4. Treatment of 
OverdoseAddition of procedural 
language Clarification added to contact the sponsor in 
case of an accidental overdose.
Section 9.3. Populations for 
Analy sis
Section 9.4.1. General 
Considerations
Section 9.4.2.2. Patient 
Characteristics
Section 9.4.6 .3. 
Hypoglycemia EpisodesChange in language related 
removal of Algorithm 2Update of statistical analy sis after removal of 
Algorithm 2
Section 10.3.3. Definition of 
an Unanticipated Adverse 
Device Effect (UADE)Rem oval of section related to 
Algorithm 2Clarification that UADE will not be 
applicable after removal of Algorithm 2
Section 10.8. Appendix 8:  
Dosing Guidance for 
LY3209590 and Insulin 
DegludecUpdated title of appendix Clarification that dosing guidance is available 
for LY3209590 and Insulin Degludec
Section 10.10. Appendix 10: 
Change to Study Procedures 
due to the COVID -19 
Pandemic or Natural DisastersAddition of language for 
Rem ote VisitsClarification that sites must receive sponsor 
approval prior to implementing site mobile 
visits and visits by a sponsor organized home 
nursing service provider to replace on -site 
visits.
Throughout the document Minor editorial and document 
formatting revi sionsThese are minor changes; therefore, they 
have not been summarized.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ....................................................................................................................... 10
1.3. Schedule of Act ivities (SoA) ...................................................................................... 11
2. Introduction .............................................................................................................. 23
2.1. Study  Rati onale .......................................................................................................... 23
2.2. Background ................................................................................................................ 23
2.3. Benefit/Risk Assessment ............................................................................................ 24
2.3.1. Protocol  Risk Mi tigation Features ............................................................................... 24
3. Objectives and Endpoints ......................................................................................... 25
4. Study Design ............................................................................................................. 27
4.1. Overall Desig n............................................................................................................ 27
4.1.1. Study  Visi ts................................................................................................................ 27
4.2. Scientific Rationale for Study  Design ......................................................................... 30
4.3. Justification for Dose .................................................................................................. 30
4.4. End of Study  Definit ion.............................................................................................. 31
5.
Study Population ...................................................................................................... 32
5.1. Inclusio n Cri teria........................................................................................................ 32
5.2. Exclusio n Cri teria....................................................................................................... 34
5.3. Lifest yle Considerat ions............................................................................................. 37
5.3.1. Meals and Dietary  Restri ctions................................................................................... 37
5.4. Screen Failures ........................................................................................................... 37
6. Study Intervention .................................................................................................... 38
6.1. Study  Intervent ion(s) Administered ............................................................................ 38
6.1.1. Selection and Timing o f Doses ................................................................................... 39
6.1.2. Speci al Treatm ent Consi derat ions............................................................................... 39
6.1.3. Medical Devices ......................................................................................................... 41
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 41
6.3. Measures to Minimize Bias:  Rando mizat ion and Blinding ......................................... 41
6.4. Study  Intervent ion Compliance ................................................................................... 42
6.5. Concomitant Therapy .................................................................................................42
6.5.1. Medicat ions that Promote Weight Loss ....................................................................... 43
6.5.2. Systemic Glucocorti coids........................................................................................... 43
6.5.3. Antihypertensive Medications ..................................................................................... 43
6.5.4. Dyslipidemia Medicat ion............................................................................................ 43
6.6. Dose Modificat ion...................................................................................................... 44
6.7. Intervention after the End of the Study ........................................................................ 44
6.7.1. Treatment after Study  Com pletion.............................................................................. 44
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 45
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 45
7.1.1. Perm anent Discont inuat ion from Study Treatment ...................................................... 45
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 57.1.2. T emporary  Discont inuat ion........................................................................................ 46
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 46
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 47
7.3. Lost to Follow up ....................................................................................................... 47
8. Study Assessments and Procedures ......................................................................... 49
8.1. Efficacy Assessments .................................................................................................49
8.1.1. Primary Efficacy  Assessment ...................................................................................... 49
8.1.2. Secondary  Efficacy  Assessments ................................................................................ 49
8.2. Safety Assessments .................................................................................................... 49
8.2.1. Physical Examinat ions................................................................................................ 49
8.2.2. Vital Signs.................................................................................................................. 49
8.2.3. Electrocardiograms ..................................................................................................... 50
8.2.4. Self-monitoring o f Blood Gl ucose (SMBG) ................................................................ 50
8.2.5. Clinical Safety  Laboratory  Assessments ..................................................................... 51
8.2.6. Safety Moni toring ....................................................................................................... 51
8.2.7. Body  Weight .............................................................................................................. 52
8.3. Adverse Events and Serious Adverse Events .............................................................. 52
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 52
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 53
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 53
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 53
8.3.5. Pregnancy ................................................................................................................... 54
8.3.6. Cardi ovascular Events ................................................................................................ 54
8.3.7. Adverse Events of Special Interest .............................................................................. 54
8.3.8. Product Complaint s.................................................................................................... 55
8.4. Treatment of Overdose ............................................................................................... 56
8.5. Pharmacokinet ics........................................................................................................ 56
8.6. Pharmacodynamics ..................................................................................................... 57
8.7. Genet ics..................................................................................................................... 57
8.8. Biomarkers ................................................................................................................. 57
8.9. Immunogenicit y Assessments ..................................................................................... 57
8.10. Health Economics ....................................................................................................... 58
9. Statistical Considerations ......................................................................................... 59
9.1. Statistical Hypotheses .................................................................................................59
9.2. Sample Si ze Determinat ion......................................................................................... 59
9.3. Popul ations for Analyses ............................................................................................ 60
9.4. Statistical Analyses ..................................................................................................... 60
9.4.1. General Considerations ............................................................................................... 61
9.4.2. Treatment Group Comparabilit y................................................................................. 61
9.4.3. Primary endpo int(s).................................................................................................... 62
9.4.4. Secondary  endpoint(s) ................................................................................................ 62
9.4.5. Terti ary/expl oratory  endpoint(s) ................................................................................. 62
9.4.6. Safety Analyse(s) ........................................................................................................ 62
9.4.7. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 63
9.4.8. Evaluat ion of Immunogenicit y.................................................................................... 64
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 69.4.9. Other Analyses ........................................................................................................... 64
9.5. Interim Analyses ......................................................................................................... 64
9.6. Data Monitoring Com mittee (DMC) ........................................................................... 64
10. Supporting Documentation and Operational Considerations ................................ 65
10.1. Appendix 1:  Regulatory , Ethi cal, and Study  Oversight 
Considerations ............................................................................................................ 65
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 65
10.1.2. Financial Disclo sure................................................................................................... 66
10.1.3. Inform ed Consent Process .......................................................................................... 66
10.1.4. Data Protection ........................................................................................................... 66
10.1.5. Disseminat ion of Clinical Study  Data ......................................................................... 66
10.1.6. Data Qualit y Assurance .............................................................................................. 67
10.1.7. Source Documents ...................................................................................................... 69
10.1.8. Study  and Si te Start and Cl osure ................................................................................. 69
10.1.9. Publicat ion Policy....................................................................................................... 70
10.1.10. Invest igator Informat ion............................................................................................. 70
10.1.11. Long -Term  Sample Retent ion..................................................................................... 70
10.2. Appendix 2:  Clinical Laboratory  Tests ....................................................................... 71
10.3. Appendix 3:  Adverse Events:  Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 74
10.3.1. Definit ion of AE......................................................................................................... 74
10.3.2. Definit ion of SAE ....................................................................................................... 75
10.3.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 76
10.3.4. Reporting of SAEs ...................................................................................................... 78
10.4. Appendix 4:  Contraceptive Guidance and Collection o f 
Pregnancy Information ............................................................................................... 79
10.5. Appendix 5:  Liver Safet y:  Suggested Acti ons and Follow -up 
Assessments ............................................................................................................... 81
10.6. Appendix 6:  New York Heart Associat ion Cardiac Disease 
Classificat ion.............................................................................................................. 82
10.7. Appendix 7:  Genet ics................................................................................................ 83
10.8. Appendix 8:  Dosing Guidance for LY3209590 and Insulin 
Degl udec .................................................................................................................... 84
10.8.1. LY3209590 Algorithm 1 (paper algorithm) .................................................................84
10.8.2. Insulin Degludec ......................................................................................................... 87
10.9. Appendix 9:  Recommended Laboratory  Testing for 
Hypersensi tivity Events .............................................................................................. 89
10.10. Appendix 10:  C hanges to Study  Procedures due to the COVID -
19 Pandemic or Natural Disasters ............................................................................... 91
10.11. Appendix 11:  Abbreviat ions...................................................................................... 93
10.12. Appendix 12: Protocol Amendment History ............................................................... 97
11. References ............................................................................................................... 102
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 71. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 2, Rando mized, Parallel, Open -Label  Com parator- Controlled Trial to 
Evaluate the Safet y and Efficacy of LY3209590 in Study  Parti cipants with Type 1 Di abetes 
Mellitus Previously Treated with Mult iple Daily  Inject ion Therapy
Short Title: A Study  of LY3209590 in Participants with Type 1Diabetes Mellitus
Rationale :
LY3209590 is a lo ng-acting insulin receptor agonist being developed for the treatment of ty pe 1
diabetes m ellitus (T 1DM ) and ty pe 2 diabetes m ellitus (T2DM) .  Thi s Phase 2 study  of 
LY3209590 will evaluate the effects of LY3209590 on glycemic control  compar ed wi th insulin 
degludec in T1DM participants previously treated with mult iple daily inject ions(MDI) therapy .
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 8Objectives and Endpoint s
Object ives Endpoints
Primary
To investigate the efficacy  of 
LY3209590 compared wit h insulin 
degludec in study  participants wi th 
T1DMHbA1c change fro m baseline to 
Week 26
Secondary
Efficacy
To investigate the efficacy  of 
LY3209590 compared wit h insulin
degludec in study  parti cipants with 
T1DMHbA1c change fro m baseline to 
Week 12
Fasting glucose change fro m baseline 
to Weeks 12 and 26
Insulin dose change for b olus insulin 
from baseline to Weeks 12 and 26
Safety
To investigate the safet y of 
LY3209590 compared wit h insulin
degludec in study  parti cipants wi th 
T1DMIncidence and rateof hypoglycemia 
events during the treatment period
Incidence of treatment -emergent 
serious AEs
Pharmacokinet ics 
To characterize the PK o f LY3209590 
in study  parti cipants wi th T1DMLY3209590 populat ion-based 
param eters, such as AUC within 
dosing interva lat Week s12 and 26
Abbreviations:  AE=adverse event; AUC = area under the curve; HbA1c =hemoglobin A1c ; 
PK=pharmacokinetics; T1DM = type 1 diabetes mellitus.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 9Overall Design
Study  I8H-MC-BDC Pis a multicenter, randomized, open -label, parallel , comparator -controlled 
Phase 2 study  with 3 study  periods.  The study  is designed to eval uate the efficacy and safet y of 
LY3209590 compared wi th insulin degludec in patients with T 1DM treated with MDI without 
interrupti on for at l east 3months.  
Disclosure Statement : This is a parallel, unblinded, treatment study  with 
2arms.
Number of Participant s:
Approximately 238participants will be rando mly assigned to study  interventi on such that 
approximately  190 evaluable participants complete the study . 
Intervention Groups and Duration :
Parti cipants will be randomized in a 1:1 ratio to receive the intervent ions listed below :
LY3209590 subcutaneously weekly, dosed per Algorithm 1
Insulin degludec subcutaneously  daily , dosed per a m odified Riddle al gorithm
The m aximum  total  durati on of  study  participat ion for each participant is up to 33 weeks, across 
the following study  periods: 
Study  Period 1:  screening and lead -in period, approximately 2 weeks
Study  Period 2:  treatm ent peri od, 26 weeks
Study  Period 3:  safety fo llow-up peri od, 5 weeks
Data Monitoring Committee: No
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 101.2. Schema

CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 111.3. Schedule of Activities (SoA)
ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Informed 
consentX
Inclusion 
and 
exclusion 
criteriaX
Randomiz
ationX
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 12ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Clinical Assessments
Height X
Body 
weightX X X X X X X X X X X XSee Section 
8.2.7 .
Blood 
pressure 
and pulse 
rateX X X X X X X X X X X XSee Section 
8.2.2.
Demo -
graphyX
Medical 
history 
(includes 
substance 
usage and 
family 
history of 
premature 
CV disease)XSubstances: 
drugs, alcohol, 
tobacco, and 
caffeine
Pre-existing 
conditions  X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 13ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Concomi -
tant 
medication 
reviewX X X X X X X X X X X X
Full 
physical 
examinationX X X X X X
12-lead 
ECGX Xd X
dX
d XdXdX X X X X
AE/SAE /
PCreviewX X X X X X X X X X X X X X X X X X X X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 14ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Laboratory Assessments
Pharmaco -
kinetic 
samples 
(LY3209590 )XeX X X X X X X X X X X XCollected for 
participants 
randomized to 
LY3209590. 
See Section 8.5. 
Serum 
pregnancy 
test (WCBP 
only)X See Section 5.1.
Urine 
pregnancy 
test (WCBP 
only)X X X XAdditional 
pregnancy 
testing may be 
performed if 
required by 
local 
regulations.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 15ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
FSH XCollect for 
women whose 
menopausal 
status needs to 
be determined.  
If menopausal 
status is known, 
thistest do es
not need to be 
collected .
Urinalysis X X X X X X
eGFR X X X X
Chemistry 
panelX X X X X X X X X X X X
Hepatitis B X
HbA1c X X X X X X X X
Hematology X X X X X X X X X X
HDL, LDL X X X X X X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 16ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Free fatty 
acidX X X X X X X X X X X X
Immuno
genicityX X X X X X X X X See Section 8.9.
C-peptide XIf the C -peptide 
was assessed in 
a non -fasting 
state at V1 and 
was >0.30 
nmol/L, the 
evaluation can 
be repeated at 
V2 in a fasting 
state
Pharmaco -
genetic 
sampleX
Nonpharma
cogenetic 
Stored 
Samples
(plasma/
serum)X X X X X X X X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 17ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Ancillary Supplies/
Diaries/
Investigational Product
Study  
participant 
training/
educationXIncludes 
diabetes 
counseling, 
hypoglycemia
Section 
8.3.7.1 ), diary 
completion, and 
CGM sensor 
replacement 
Dispense 
supplies X X X X X X X XParticipant 
diaries will be 
visit specific.  
All of the 
diaries will be 
electronic .
IWRS X X X X X X X X X X X X X X X X X X X X X X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 18ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Remind 
participants 
to do cument
6-point 
glucose
profiles in 
the week 
prior to next 
indicated 
visitX X X X
X XSee next line 
for indicated 
visits.  See 
Section 4.1.1
for additional 
details.
Review 
6-point 
SMBG 
profilesX X X XX X X
Review diary 
data and 
make dose 
individualiz -
ation 
assessmentX X X X X X X X X X X X X X X XAssessment 
performed per 
participant 
assigned group 
(Algorithm 1 or 
insulin degludec)
Dispense IP X X X X X X X X X X X X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 19ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
Study  
personnel 
administer 
IP at siteX X X X X X X X X
Train 
participants
in IP 
administra -
tionX X X X XIP can be self -
administered by 
study  
participants 
Weeks 13- 25. 
Information on 
self-injection 
can be 
reviewed as 
necessary 
throughout the 
study .
Study  
participant 
CGMf
trainingX
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 20ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
CGM 
sensor 
insertion at 
siteX
Distribute 
CGM 
sensor if 
necessaryX X X X X X X X X X X X X X X X X X XPatients will 
replace CGM 
sensor every 10
days at home 
and will be 
trained for this 
procedure at 
Visit 2.  At 
each visit 
patient will be 
supplied with 
the necessary 
sensors for the 
respective 
interval
CGM data 
downloadX X X X X X X X X X X X X X X X X X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 21ProcedureStudy 
Period 
1
Screen
ing
and
Lead -inStudy Period 2
Treatment PeriodEarly 
Discontinua
tionStudy 
Period 
3
Follow
-upET Notes
eCRF Visit 
Number1 2 3a4 5 6 7 8 9 10 11 12 13 14 15 16b17 18 19 20cED1 ED2c801c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 14 16 20 24 26ED1 
+531
Visit 
window, 
days±
7±
3±
2±
2±
3±
2±
2±
3±
2±
2±
2±
2±
2±3 ±3 ±3±
3±3 ±3 ±3 ±3 ±3
Fasting X X X X X X X X X X X XMinimum 8 
hours
LY3209590 
and insulin 
degludec 
accounta -
bility 
(collect 
used and 
unused IP)X X X X
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 22Abbreviations:  AE = adverse event; BG = blood glucose; CGM = Continuous Glucose Monitoring; CV = cardiovascular; ECG = electrocardiogram; eCRF = 
electronic case report form; eGFR = estimated glomerular filtration rate; ET = early termination; FSH = follicle -stimulating hormone ;HbA1c = glycated 
hemoglobin; HDL = high density lipoprotein; HIV = human immunodeficiency virus; IP = investigational product; IWRS = interactive web response system; 
LDL = low density lipoprotein; LY = LY3209590; PC = product complaint ; PK = pharmacokinetics; SAE = serious adverse event; SMBG = self -monitoring 
blood glucose; WCBP = women of childbear ing potential.
aAll measures to be performed at Visit 3 should be done prior to injection of the participant’s assigned investigational produ ct (IP) to ensure that appropriate 
baseline measurements are obtained.
bVisit 16 is a Phone visit.
cVisits 20 an d ED1 are performed approximately 1 week after the last dose of LY and 1 day after the last dose of degludec.  V isit 801 is performed for 
participants who complete V isit 20.  ED1 and ED2 are performed for participants who discontinue study drug but remain in the study.  
dA triplicate, central ECG will be performed in a fasting state at Visits 3, 6, 9, 15, and 17, prior to each PK sample. Patients randomized to insulin degludec 
treatment will undergo ECG in a fasting state without PK sampling.   Only one triplicate ECG is needed for insulin degludec treated patients.
eCollect 2 PK samples of LY3209590 :  1 predose and one approximately 2 hours postdose or as late as possible just prior to departure from the site. ECG will 
be performed in triplicate prior to the time of each PK sampling at this visit. Note:  PK samples are not intended to be collected for participants in the insulin 
degludec treatment group.
fPatients will be fitted with Dexcom G6 ®for CGM monitoring.
Note:  Additional visits t o ensure correct dosing, titration ,and study drug administration can occur anytime during the study if deemed necessary by the 
investigator and are explicitly allowed and part of the protocol.
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 2 3 2. I ntr o d ucti o n 
2. 1. St u d y R ati o n ale 
L Y 3 2 0 9 5 9 0 is a l o n g- acti n g i ns uli n rece pt or a g o nist bei n g de vel o pe d f or t he treat me nt of t y pe 1
di a betes m elli t us ( T 1D M )a n d t y pe 2 dia betes m elli t us (T 2 D M ).  T hi s P hase 2 st u d y  of  
L Y 3 2 0 9 5 9 0 will e val uate t he effects of L Y 3 2 0 9 5 9 0 o n gl yce mic c o ntr ol c o m pare d wit h i ns uli n 
de gl u dec i n T 1 D M pat ie nt spre vi o usl y treate d wit h m ult i ple dail y  i nject i o n ( M DI) t hera p y .
2. 2. B ac k gr o u n d 
L Y 3 2 0 9 5 9 0 was desi g ne d as a n o vel, o nce -wee kl y, l o n g- act i n g i ns uli n rece pt or a g o nist t hat is 
i nt e n de d f or t he treat me nt of h y per gl yce mia i n st u d y  p arti ci pa nts wi t h  T 1D M a n d T 2 D M .  I n real 
life, o nl y a b o ut 3 0 % of patie nts wit h T 1 D M i n t he U nite d Ki n g d o m ( U K )reac h t he tar get 
H b A 1c o f <7. 5 % ( 5 8 m m o l/ m o l) ( N D A 2 0 1 7 ), a n d a o nce -wee kl y  i ns uli n rece pt or a g o nist c o ul d 
hel p t o i ncrease t his n u m ber.   T he p ote ntial d o w nsi de of s uc h a l o n g -acti n g i ns uli n rece pt or 
a g o nist c o ul d t he oreticall y be a hi g her ris k f or h y p o gl yce mic e ve nts or a l o n ger d urati o n of  s uc h 
e ve nts.  I n c o n trast t o t his t he oretical ris k t he l o n g -acti n g i ns uli n de gl u dec has s h o w n a re d uce d 
p ote nti al  t o i n d uce h y p o gl yce mia as c o m pare d t o i ns uli n glar gi ne w hile its half -life is t wice as 
l o n g as t hat of i ns uli n glar gi ne ( Heise et al. 2 0 1 2 ).  T he c urre nt P hase 2 st u d y  will  t h er ef or e 
e val uate t he safet y a n d efficac y of  L Y 3 2 0 9 5 9 0 c o m pare dt o i ns uli n de gl u dec w hile ver y  cl os el y  
m o nit ori n g gl yce mic pr ofiles. 
P hase 1 st u dies e val uat i n g t he p har mac o ki net ic s( P K) a n d p har mac o d y na mic s( P D) effect o f 
L Y 3 2 0 9 5 9 0 i n heal t h y v o l u nt eers a n d pat ie nt s wi t h T 2 D M ha ve bee n c o m p lete d.  Data fr o m 
, w hic h was t he si n gle -asce n di n g d ose ( S A D) st u d y , d e m o nstrate d cl ear e vi de nce of 
gl uc ose l o weri n g i n st u d y  p arti ci pa nts wi t h  T 2 D M f o ll o wi n g si n gle d oses of L Y 3 2 0 9 5 9 0 ra n gi n g 
fr o m  m g.  T he P K of L Y 3 2 0 9 5 9 0 f o ll o wi n g si n gle d oses de m o nstrate d pr ol o n ge d ti me -
acti o n pr ofile t o s u p p ort o nce -wee kl y  a d mi nistrati o n.  L Y 3 2 0 9 5 9 0 reac he d ma xi m u m 
c o nce ntrati o n a p pr o xi matel y 4 da ys after d osi n g, f oll o we d b y a mea n eli mi nat i o n  
 i n st u d y  partici pa nts wi t h  T 2 D M.  Wit h a 
l o n g eli mi nat i o n half -life, f o ll o wi n g a wee kl y  fi x e d -d ose re gi me n, P K stea d y -state was pre dicte d 
t o be reac he d i n  wit h a p pr o xi matel y  hi g her c o nce ntrati o n 
d ue t o acc u m ulati o n t ha n after si n gle d ose.  T heref ore, base d o n P K m o deli n g a l oa di n g d ose 
strate g y   ti mes t he wee kl y  d os e w o ul d ac hie ve stea d y -state e x p os ure after 1 d ose.  Base d o n 
data i n st u d y  B D C B, t he m ulti p le -asce n di n g d ose ( M A D) st u d y , P K f o ll o wi n g a si n gle l oa di n g 
d ose ( t he i nit ial wee kl y d ose) d uri n g t he first wee k was de m o nstrate d t o be c o m para ble t o 
c o nce ntrati o n pr ofile at Wee k 6 (at d ose deli vere d o nce wee kl y), s u p p orti n g t he l oa di n g d ose 
strate g y .  N o cli nicall y si g nifica nt persiste nce i n h y p o gl yce mia was o bser ve d i n t he st u d y .  
Besi des t he k n o w n ris k of h y p o gl yce mia, n o rele va nt safet y si g nals ha ve bee n o bser ve d i n t he 
P hase 1 st u dies.  
T he t o xi ci t y  pr ofile of L Y 3 2 0 9 5 9 0 has bee n c har a ct eri ze d i n 6 -wee k a n d 6 -m o nt h re peat -d ose 
t o xi c o l o g y  st u di es i n rats a n d d o gs, a n d re pr o d ucti ve t o xic o l o g y  st u di es i n rats a n d ra b bits.  
T hese st u dies de m o nstrate d a fa miliar s pectr u m of effects t y picall y  ass o ci at e d wi t h  c ha n ges 
sec o n dar y  t o h y p o gl yce mia a n d/ or h y peri ns uli ne mia res ult i n g fr o m re peat d osi n g of e x o ge n o us C CI 
C CI 
C CI 
C CI C CI 
C CI 
C CI 
C CI 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 24insulin in normoglycemic test sy stem s.  All  findings were consi dered to be target -related with no 
evidence of off- target effects in any  of the param eters assessed.  
Addit ional information about LY3209590 can be found in the Invest igator’s Brochure (IB).
2.3. Benefit/Risk Assessment
The data from the SAD study  and the MAD study  (studies BDCA and BDCB , respect ively ),as 
well as the ongoing Phase 2 BDCM study have shown that LY3209590 was well tole rated and 
the adverse drug reactions are in line wit h those reported for long -acting insulins.
Potenti al risks associated wi th LY3209590, deriv ed from the known ri sks of l ong-acting insulins
are hypoglycemia, hypersensit ivity react ions (localized allergy a nd/or sy stemic allergy ),
undesirable effects at the inject ion site (inject ion
-site reacti ons and lipody strophy ), and
peripheral  edema. Besides the expected risk of hypoglycemia, serious presentations of the listed 
side effects have not been observed in st udy parti cipants or healthy volunteers exposed to 
LY3209590 for up to 12 weeks.
Taking into account the measures taken to minimize risk to participants in this study , the 
potenti al risks i dentified in associat ion with LY3209590 are justified by the anticip ated benefits 
that may  be offer ed to parti cipants wi th T1DM .
More informat ion about the known and expected benefits, risks, Serious Adverse Events (SAE s
), 
and reasonably ant icipated adverse events ( AEs)of LY3209590 may be found in the IB.
The Algori thm 1(paper) wasdeveloped to init iate and guide LY3209590 dose adjust ment for 
this study  to safely and efficient ly achieve gly ce
mic goal s. 
2.3.1. Protocol Risk Mitigation Features 
Methods to minimize potential risks are relevant for parti cipants assigned to LY3209 590 
Algori thm 1 and insulin degludec treatment groups.  These include:
Thorough training on the protocol design elements and inclusion/exclusio n criteria; use 
of an electroni c diary ( eDiary ), aweb-interface,and reporting system alo ng with 
availabilit y ofassoci ated instruction manuals and reference documents .
Careful data validat ion:  After patient -reported data has been entered and synced 
remotely  to the central  web server, the investigator is able to view the data through the 
web portal and generate sum mary  reports.  An important feature of the study  requi res 
careful review of the reported informat ion with the pati ent and verificat ion of its 
accuracy  at each study  visit. 
Email notification to invest igator any time the patient reports a potential severe episode 
of hypoglycemia (requiring assistance due to neurological impairment) in the eDiary .
Specific criteria for fast ing or persistent hy perglycemia are described protocol 
Section6.1.2.3 .
Use of CGM wit h appropriate low/high glucose alarms throughout the study.
Importantly, in both treatm ent groups, the final dosing decisio ns remain subject to clinical 
judgement of the invest igator.  Decisions to override an algorithm reco mmended dose are 
docum ented in the electroni c case report form ( eCRF )for Algorithm 1 and insulin degludec .
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 253. Objectives and Endpoints
Object ives Endpoints
Primary
To investigate the efficacy  of 
LY3209590 compared wi th insulin 
degludec in study  parti cipants wi th 
T1DMHbA1c change fro m baseline to 
Week 26
Secondary
Efficacy
To investigate the efficacy  of 
LY3209590 compared wit h insulin
degludec in study  parti cipants with 
T1DMHbA1c change fro m baseline to 
Week 12
Fasting glucose change fro m baseline 
to Weeks 12 and 26
Insulin dose change for b olus insulin 
from baseline to Weeks 12 and 26
Safety
To investigate the safet y of 
LY3209590 compared wit h insulin
degludec in study  parti cipants with 
T1DMIncidence and rate of hypoglycemia 
events during the treatment period
Incidence of treatment -emergent 
serious AEs
Pharmacokinet ics 
To characterize the PK o f LY3209590 
in study  parti cipants wi th T1DMLY3209590 populat ion-based 
param eters, such as AUC within 
dosing interval at Week s12 and 26
Tertiary/Exploratory
To establish the equivalent dose of 
LY3209590 relat ive to insulin 
degludecInsulin dose at baseline and Week 26
To investigate the safet y and 
tolerabilit y of LY3209590 compared 
with insulin degludec in study  
participants with T1DMTreatment -emergent AEs
Incidence and rate of hypoglycemia 
events during the post -treatm ent 
follow-up period
Discontinuati on of  IP due to AEs
Clinical laboratory  resul ts
System atic assessment of inject ion site 
react ions
Insulin dose for prandi al as well  as 
basal insulin during treatm ent peri od 
and follow-up peri od
Incidence and rate of hypoglycemia 
during treatment and follow -up peri od
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 26Object ives Endpoints
Incidence and rate of day time 
hypoglycemia
Liver aminotransferase change fro m 
baseline to Weeks 12 and 26
Triglyceride and FFA change from 
baseline to Weeks 12 and 26
Body  weight change from  baseline to
Weeks 12 and 26
To expl ore quali ty of glycemic control  
compared wi th insulin degludec using 
CGMGlucose time in target range, time in 
hyperglycemia, time in hypoglycemia
Durati on of  hypoglycemic events
To establish the relat ionships between 
dose/exposure and key  safet y and 
efficacy  measures for LY3209590 LY3209590 exposure -response 
relationships for key  efficacy and 
safet y measures (e.g.,glycemic 
control , hypoglycemia and safet y 
labs).
To characterize the effects of 
LY3209590 on exploratory  PD 
biomarkers
To expl ore the development of 
LY3209590 ADAs
To expl ore the com pliance wi th the 
dosing regimenLipids (cho lesterol , LDL, HDL, 
triglyceri des)
6-point SMBG glucose profiles
Biomarkers of lipolysis (FFA)
The frequency of ant ibody  formati on 
to LY3209590 and relat ionship to 
safet y and efficacy markers will be 
determined
Incidence and percentage of missed 
doses of LY3209590 and insulin 
degludec.
Abbreviation s:  ADA =antidrug antibodies; AE =adverse events; AUC =area under the curve; CGM =continued 
glucose monitoring; FFA = free fatty  acids; HbA1c =glycated hemoglobin; HDL =high density lipoprotein; 
IP=investigational product; LDL =low density lipoprotein; PD =pharmacodynamics; SMBG =self-monitoring
blood glucose; T1DM =type 1 diabetes mellitus .
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 274. Study Design
4.1. Overall Design
Study  I8H-MC-BDC P(BDCP) is a mult icenter, rando mized, open -label, parallel, co mparator -
controlled Phase 2 study  with 3 study  periods.  The study  is designed to evaluate the efficacy and 
safet y of LY3209590 compared wit h insulin degludec in patients with T1DM treated with MDI 
for at least 3 m onths pri or to screening.
The study  will consist of 3 peri ods:  
Study  Period 1:  screening and lead -in period, approximately 2 weeks
Study  Period 2:  treatm ent peri od, 26 weeks
Study  Period 3:  safety  follow-up peri od, 5 weeks
The study  schema is presented in Sect ion 1.2.
Study  governance considerations are described in detail in Section10.1.
4.1.1. Study Visits
Study Period 1:  Screening and Lead -in
The purpose of procedures at screening is to establish eligibilit y for incl usion in the study  (see 
Secti ons 5.1and 5.2.  During this period (upon signing the informed consent form [ ICF] ), study  
participants will be trained on disease monitoring and disease management procedures, study  
diaries, and study  procedures.  
Electronic participant diaries and participant paper note sheet swill be dispensed at Visit 2 and as 
specified in the Sche dule of Act ivities (Section 1.3)for future vi sits. Collect ion of baseline self-
monitoring bl ood gl ucose ( SMBG )profiles via continuous glucose mo nitoring ( CGM )will start 
at Vis
it 2.  Parti cipants will cont inue on their same regimen of basal and short acti ng insulin 
during the lead- in period up to randomizat ion.  
A participant will be considered ineligible and will be discontinued from a trial bef ore 
rando mizat ion if they: 
initiate agents that are prohibited (Secti on 6.5), or
initiateinsulin pump treatm ent (Section 5.2)
For all study  participants m eeting study  entry  criteria, the Dexco m G6®CGM device will be 
inserted and activated at (Visit 2).  TheCGM sensor, transmitter and receiver will be distributed 
to the parti cipant as needed per the Schedule of Activit ies(Secti on 1.3).  
SMBG :
Parti cipants will record two 6-point glucose profiles ( using the CGM device) at non-consecut ive 
days between V isit 2 and V isit 3.  The profile should include readings before and 2 hours after 
each m ajor m eal of the day  (breakfast, l unch, and dinner).  
Continuous Gl ucose Moni toring (CGM)
A standard system , Dexcom  G6, will be used according to manufacturer’s direct ions for CGM in 
an unblinded mode.  The study  partici pants will wear this device beginning at V isit 2, as shown 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 28in the Schedule of Act ivities (Sec tion 1.3).  In additi on, all  study  parti cipants will be allowed to 
use their personal blood glucose (BG) meters for addit ional BGtesting, or for ta king SM BG 
measurements during the outpatient period. Therapeutic decisio ns will be based on the CGM 
readings. Blood gl ucose m eters m ust not be used to calibrate the CGM device.  CGM calibrat ion 
must be done using the code provided with each sensor. Participants m ust use the study -specific 
CGM receiver and are not allowed to connect the transmitter of the CGM system to a personal 
smartphone to ensure data availabilit y for downl oad from  the receiver at the respective visits as 
described in the Schedule of Activities (Section 1.3).
At Visit 2, study  parti cipants who fulfill eligibilit y criteria will be trained on the use of the CGM 
device, CGM sensor repl acement, interpretation of CGM -based BGvalues and alarms, and the 
requi rements for CGM.  For the first CGM sessio n, study  participants meet ing all study -entry  
criteria will have the CGM sensor inserted as part of the Visit 2 activit ies.
Study Peri od 2:  Treatment Period
Randomization
Parti cipants who continue to be eligible for the study  will be rando mized to 1 of the 2 treatm ent 
groups.  All measures, including a urine pregnancy test, to be performed at Visit 3 (see Schedule 
of Activities, Secti on1.3) should be done prior to inject ion of the participant’s assigned 
investigat ional product (IP) to ensure that appropriate baseline measurements are obtained.  The 
participant will begin IP if the urine pregnancy test is negative.  If the result of the seru m 
pregnancy test is posit ive, the participant will be discontinued from the study (see Section 7.2)
Study  personnel will inject the first dose of IP at the study site.  The PK sample and 
electrocardi ogram s (ECGs) at randomizat ion must be co llected as described in the Schedule of 
Activities (Section 1.3).
Treatment
Following rando mizat ionat Visit 3, parti cipants will part icipate in a 26-week treatment period. 
For pati ents randomized to the LY3209590 arm the fo llowing gui dance for IP administration is 
applicable:
During Weeks 0to 8, site personn el will administer IP at the site.  Participants will 
receive educat ion and training on how to self-administer IP (for details, see the Schedule 
of Activities).  The training should include information on reconstitution of IP, 
appropriate inject ion site locat ions, inject ion technique, and the signs and symptoms of 
local adverse react ions, shoul d thoseoccur.   
During Weeks 9 to 12, IP will be reconst ituted and administered at the site by the 
participant, under supervisio n of tra ined site personnel to assure that the participant is 
capable of self -administrati on. 
During Weeks 13 to 25, outside of titration visits IP can be self -administered by  the 
participant at hom eunless local regulat ions requi re administrati on at the si te, or 
optionally  can be administered once weekly  by si te personnel .  
Inform ation on self -inject ioncan be reviewed as necessary  throughout the study . 
Addit ional visits to ensure correct dosing, titration, and study  drug administration can 
occur any time durin g the study  if deemed necessary  by the invest igator.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 29LY3209590 will be administered as follows :  
Algori thm 1(paper al gorithm):dose adj ustment guidance provi ded; study  participant
will receive an individualized LY3209590 loading dose on Day  1 wi th weekl y 
adjustm ents based on fasting glucose ( FG)and hypoglycemia data for the first 
12weeks, then every 4 weeks .
For pati ents randomized to LY3209590 Algorithm 1, documented guidance for dose adjustment 
isprovi ded (Secti on 10.8). 
For pati ents randomized to the insulin degludec arm the following guidance for administration is 
applicable .
Insulin degludec will be self -administered daily  by parti cipants after a training and first 
administration under site personnel supervisio n on Day  1 according to a m odified Riddle 
algorithm (Secti on 10.8).
General considerat ions
Study  procedures will be performed as listed in the Schedule of Activit ies (Secti on 1.3).  
To allow timely sampling for PK assessments, visits for collect ion of the samples will be 
scheduled within the required time windows provided in the Schedule of Act ivities(Secti on 1.3).
Parti cipants will cont inue to use concomitant short- acting insulin throughout the treatment 
period.  Discont inuat ion or changes to regimen are not permitted, except in situat ions where dose 
adjustm ent is requi red for medical reasons or when allowed per study  protocol  (see Secti on 6.5).  
Study  parti cipants will be instructed to document fasting glucose (FG) each day in their 
electroni c diary (eDiary ) by using the values displayed on their CGM device aft er wakening.  In 
addition, two 6-point SMBG profiles (prior to and 2 hours after the morning, midday, and 
evening meals) should be done on nonconsecut ivedays in the week prior to the required visits 
noted i n the Schedule of Activit ies(Secti on 1.3). 
Parti cipants who devel opsevere , persi stent hyperglycemia based on prespecified thresho lds (see 
Secti on6.1.2.3 )will receive a n unscheduled intensificat ion of their insulin treatment based on 
clinical judgment of the invest igator with a parallel informat ion ofLilly Medical by email.  
Parti cipants who need unscheduled intensification of their insulin treatment will continue on IP 
in the trial unt il they co mplete all study  visits.  
Study Period 3: End-
of-Treatment and Safety Follow -up, Visits 20, 801, Early 
Discontinuation 1 and 2 (ED1 and ED2)
All randomized participants shoul d have a com prehensive efficacy and safet y evaluation 
approximately  1 week after the l ast dose of LY3209590 and 1 day  after the l ast dose of insulin 
degludec , and a safet y follow-up visi t approximately  6 weeks after the l ast dose of LY3209590 
and 5 weeks after the last dose of insulin degludec .  During the safet y follow-up study  period, 
participants will cont inue CGM andwill be switched back to their previous lyused basal insulin 
therapy  if appropri ate(see Section 6.7.1 ).  Parti cipants will also be requi red to return any  
remaining used or unused IP at Vis it 20 and the eDiary at Visit 801 to the invest igative site.
Parti cipants who complete the treatment period will have a com prehensive End- of-Treatment 
efficacy  and safety  assessment (Week 26; Visit 20) approximately 1 week after the last dose of 
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 3 0 L Y 3 2 0 9 5 9 0 a n d 1 da y  af t er la st d ose of i ns uli n d e gl u dec a n d a safet y  f ol l o w- u p assess me nt 
( Vi si t 8 0 1) a p pr o xi matel y 6 wee ks after t he last d ose of L Y 3 2 0 9 5 9 0 a n d 5 wee ks after t he last 
d ose of i ns uli n de gl u dec .  
P arti ci pa nts w h o disc o nti n ue I P pri or t o c o m pleti o n of  t he treat m e nt peri o d f o r a n y  reas o n 
s h o ul d f o ll o w t he visit sc he d ule off st u d y  dr u g a n d al s o ha ve a c o m pre he nsi ve E n d -of -Treat me nt 
efficac y  a n d safet y  assess me nt ( E D 1 ) a p pr o xi matel y 1 wee k after t he last d ose of L Y 3 2 0 9 5 9 0 
a n d 1 da y  af t er t h e last d ose of  i ns uli n de gl u dec or as s o o n as reas o na bl y p ossi ble t hereafter, a n d 
s h o ul d ha ve a safet y f o ll o w- u p assess me nt ( E D 2 ) a p pr o xi matel y 6 wee ks after t he last d ose of 
L Y 3 2 0 9 5 9 0 a n d 5 wee ks after t he last d ose of i ns uli n de gl u dec .  St u d y  act i vit ie s at Vi si ts  E D 1 
a n d E D 2 are i de nt ical t o Wee k 2 6 ( Vi si t 2 0) a n d Vi si t 8 0 1, res pecti vel y. T his cl ose f o ll o w- u p i s 
necessar y  si nce L Y 3 2 0 9 5 9 0 has a  a n d t he s witc h t o a n 
al ter nat i ve, c o m merciall y a vaila ble i ns uli n m ust be cl osel y m o ni t ore d t o pre ve nt h y p o gl yce mia 
d ue t o a n acc u m ulat i o n of i ns uli n acti o n.  
P arti ci pa nts w h o di sc o nti n ue I P pri or t o t h e c o m pl eti o n of  t he treat m e nt peri o d will be 
e nc o ura ge d t o re mai n i n t he st u d y  a n d t o c o m plete a n y sc he d ule d st u d y  pr oce d ures t hat occ ur 
u n ti lVisi t 2 0 .  Parti ci pa nts re m ai ni n g i n t he st u d y  wi ll recei ve a n a p pr o priate gl uc ose -l o weri n g 
re gi me n.  
P arti ci pa nts w h o disc o nti n ue I P f or a ny re as o n a n d are u n w illi n g t o ret ur n f or a s afety f oll o w - u p 
visit, will be as ke d t o perf or m a n earl y  ter mi nat i o n ( E T) visit as t h ei r fi nal  st u d y  visit .  At t his 
visit, partici pa nts will p erf or m  pr oce d ures liste d i n t he Sc he d ule of Act i vit ies ( Secti o n 1. 3 ). 
4. 2. Scie ntific R ati o n ale f or St u d y Desi g n 
T his st u d y  will  e v al uate L Y 3 2 0 9 5 9 0 i n pat ie nt s wit h T 1 D M, c o m pare d wit h a n acti ve c o ntr ol.  
T he st u d y  will  l ast 2 6 wee ks t o ha ve a n a de q uate d urati o n of  e x p os ure necessar y  t o assess 
efficac y  a n d safet y  of  L Y 3 2 0 9 5 9 0 .
I ns uli n de gl u dec is a n u n bli n de d acti ve c o m parat or i n t his st u d y  a n d will  be use d t o c o m pare t he 
effects of L Y 3 2 0 9 5 9 0 o n gl yce mic c o ntr ol, h y p o gl yce mia, a n d wei g ht gai n wit h a dail y basal 
i n s uli n. 
4. 3. J u stific ati o n f or D ose 
 
 
a si n gle l o a di n g d ose , f oll o w e d b y wee kl y d ose a dj ust me nt s is 
rec o m me n de d f or L Y 3 2 0 9 5 9 0 d osi n g re gi me n.  T he l o a di n g d ose is deter mi ne d base d o n t h e 
pati e nt 's pre vi o usl y use d basal i ns uli n d ose, baseli ne fast i n g gl uc ose, a n d a vaila ble L Y 3 2 0 9 5 9 0 
data t o i nf or m t he l oa di n g d o se strate g y .  D ose a dj ust me nts are base d o n pri or fasti n g gl uc ose 
a n d h y p o gl yce mia e ve nts.  Alterati o ns t o t he d oses rec o m me n de d b y t hese d ose a dj ust me nt 
al g ori t h ms are al s o u n der discreti o n of t he i n vest i g at or a n d will ta ke h y p o gl yce mia a n d ot her 
st u d y  partici pa nt safet y  c o ncer ns i nt o acc o u nt. I n case of a de viati o n fr o m t h e al g ori t h m -
rec o m me n de d d ose ,a m e dical rati o nale f or t hi s de viat i o n m u st be d oc u m e nte d b y  t he pri nci p al 
i n vesti gat or .C CI C CI 
C CI 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 31The starting dose for insulin degludec is the same dose as the basal insulin that the study  
participant used prior to entering the study .  The study  parti cipant will  start a ti tration phase 
based on FGand the presence of hypoglycemia or other safet y concerns.  Dose adjust ments will 
be perform ed according to a modifie d Riddle algori thm, which is wi dely used in clinical trials 
and clinical pract ice (Sect ion10.8).  
As it may be desirable to achieve therapeutic goal of LY3209590 in less than 12 weeks with low 
risk of hyper glycemia , an ini tiation dose strategy  may be appropri ate where the first dose 
sufficient to achieve an efficacious exposure is given init ially, fo llowed by individually  
optimized weekly  dose adj ustm ents to achieve target response. Table forAlgorithm 1 shows the 
loading doses, as well as those to be used when adjusting the dose during the dose -
individualizat ion visit s.  See Section 10.8 for descript ion of the dose adjustment algorithms. 
Guidance i s provi ded f or dosing suggest ions for investigators based on FGand hypoglycemia of 
the study  parti cipant ( Section 10.8).
Safety of study  parti cipants will be closely mo nitored during the early stages of dose titration to 
determine whether adjust ments to the conve rsion and dose adj ustment algorithmis needed.  As 
additional data em erges, gui dance fro m the sponsor on these dosing algorithms may be modified 
(Secti on10.8). 
4.4. End of Study Definition
End of the trialis the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities(Secti on 1.3) for the l ast patient.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 325. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Type of Study Participant and Disease Characteristics
[1] Have a diagnosis of T1DM for at least 1 y ear.  Adiagnosis of T1DM is based 
on medical history  with a fasting C -pepti de ≤0.30 nmo l/Lat screening or 
before rando mizat ion.
[2] Have been using MDIs wit hout interruption for at least 3 months prior to 
screening .
Study Participant Characteristics
[3a]No m ale contraception required except in compliance wit h specific local 
government study  requi rements.
[3b]Female participants :
1)Women of child- bearing potenti al who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a s ame sex 
relationship (as part of their preferred and usual lifest yle) must agree to 
either rem ain abst inent or stay in a same sex relat ionship wit hout sexual 
relationships wit h males. Periodic abst inence (e.g., calendar, ovulat ion, 
symptothermal, post -ovulation methods), decl aration of abst inence just for 
the duration of a trial, and wit hdrawal are not acceptable methods of 
contraception.
2)Otherwi se, women of child -bearing potential participat ing must agree to 
use 1highly effect ive method (l ess than 1% fai lure rate) of contraception, 
or a combinat ion of 2effect ive methods of contraception for the ent irety of 
the study .
a)Women of child- bearing potenti al parti cipat ing must test negative for 
pregnancy prior to init iation of treatm ent as indicated by  a negat ive
serum  pregnancy  test at the screening visit followed by  a negat ive urine 
pregnancy test within 24 hours prior to exposure.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 33b)Either 1highly effect ive method of contraception (such as combinat ion 
oral contraceptives, implanted con tracepti ves or intrauterine device) or 
a combinat ion of 2effective methods of contraceptio n (such as male or 
female condo ms with spermicide, diaphragms wit h spermicide or 
cervical sponges) will be used. The participant may choose to use a 
doubl e barri er method of contraception.  B arrier protecti on methods 
without concomi tant use of a spermicide are not a reliable or acceptable 
method. Thus, each barrier method must include use of a spermicide. 
It should be noted that the use of male and female condoms as a double 
barrier m ethod i s not consi dered acceptable due to the high failure rate 
when these methods are combined.
3)Women not of childbearing potential may participate and include those 
who are:
a)infertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal ligation), congenital ano maly such as mullerian 
agenesis; or
b)post-menopausal –defined as either
i)A wo man at l east 40 years of age with an intact uterus, not on 
horm one therapy , who has cessat ion of menses for at least 1 y ear 
without an al ternat ive medicalcause, AND a follicle-stimulat ing 
horm one(FSH) >40 mIU/mL; or
ii)A wo man 55 or older not on hormone therapy , who has had at l east 
12 m onths of spontaneous amenorrhea; or
iii)A wo man at l east 55 years of age with a diagnosis of menopause 
prior to starting horm one replacement therapy .
[4] Are at l east 18 y ears of age, at the time of signing the informed consent.
[5]Have H bA1c values of 5.6% to 9.5% inclusive , as determined by the central 
laboratory at screening .
[
6]Have been treated with a stable regimen of once -or twi ce-daily insulin 
glargine (U-100 or U -300) , insulin detemir,or insulin degludec (U-100 or 
U-200) for 3 months prior to screening.
[7] Are c urrent ly treated with the same SC rapid -acting analog insulin (insulin 
lispro U -
100or U-200, insulin aspart, FiAsp, or insulin glulisine) in MDI for 
at least the l ast 30 day s prior to screening .
[8] Have a body  mass index ( BMI )≤35 kg/m2, with no si gnificant wei ght gain or 
loss in the past 3 m onths ( ≥5%) .
[
9]In the invest igator’s opinio n, are w ell-motivated, capable, and willing to:
learn how to self
-inject treatm ent;
maintain study  diaries, as required for this protocol; 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 34wear study -provi ded CGM (Dexco m G6) during the complete study  
durati on wi thout interruption and use this device for therapeu tic decisio n-
making ;
must have a normal wake/sleep pattern such that midnight to 0600 hours 
will reliably reflect a usual sleeping period .
[10] In the invest igator’s opinio n, are proficient in: 
counting carbohydrates 
adjusting meal -and correcti on boluses based on glucose readings with a 
stable insulin/carbohydrate rati o as well  as correction factors
adjusting insulin and di etary  therapy  during special situat ions (e.g.,
exercise ,stress, intermittent diseases )
[
11]Are willing and able to fo llow the visit schedule during the complete duration
of the tri al.
Informed Consent
[
12]Capable of giving signed informed consent as described in Section10.1, 
which includes co mpliance wit h the requirements and restrictions listed in the 
ICF and in this protocol .
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing c riteria apply:
Medical Conditions
[
13] Have had more than 1 emergency room visit or hospitalization due to poor 
glucose control  (hyperglycemia or diabet ic ketoacidosis [DKA]) within 
6months pri or to screening.
[
14]Have had any  episodes of severe hypoglyc emia (defined as requi ring 
assistance due to neurologically disabling hypoglycemia) and/or
hypoglycemia unawareness within the 6 m onths prior to screening .
[15]Have s ignificant lipohypertrophy , lipoatrophy , scars, or h/o abscess in areas of 
inject ion
.
[16] Have visio n or hearing loss that impairs recognit ion of CGM screens, alerts 
and alarms .
[17]Cardi ovascular (CV):  have had any of the fo llow CV condi tions: acute 
myocardial  infarct ion, New York Heart Association Class III or IV heart 
failure ( Secti on10.6), or cerebrovascular accident (stroke)
[18]Gastrointestinal:  have gastroparesi s or have undergone gastri c bypass 
(bariatric) surgery  or restri ctive bariatric surgery ( e
.g., Lap -Band®) prior to 
screening
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 35[19] Hepati c:  have acute or chronic hepat itis, or obvious clinical signs or 
symptoms of any other liver disease except non -alcoholic fatty  liver di sease 
(NAFLD) (i.e., patients with NAFLD are elig ible for participat ion), and/or 
have elevated liver enzyme measurements, as determined by the central 
laboratory  at screening and as indicated below:
Total  bilirubin level (TBL) >2x the upper limit of normal (ULN), or
Alanine aminotransferase ( ALT )/serum  glutamic pyruvic transaminase 
(SGPT) >2.5x ULN, or
Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase 
(SGOT) >2.5x ULN
[20]Renal:  
Have history  of renal  transplantati on
Are current ly receiving renal dialysis
Have s erum  creat inine >2.0 m g/dL (177 µm ol/L) at screening, or
Have an estimated glomerular filtration rate ( eGFR
)of 
<30mL/min/1.73 m2
[21] Have experienced significant weight loss or gain (>5%) in body  weight in the 
3 months pri or to screening.
[
22]Have act ive or untreated malignancy, or have been in remissio n from
clinically significant malignancy (other than basal cell or squamous cell skin 
cancer) for less than 5 y ears or are at increased risk for developing cancer or a 
recurrence of cancer in the opinio n of the invest igator.
[
23]Have known hypersensit ivity or allergy  to any  of the study  medicat ions or 
their excipients .
[
24]Have any other serious disease or condit ion (e.g., known drug or alcoho l 
abuse /regular consumpt ionor psy chiatri c disorder) that, in the opinio n of the 
investigator, would pose a significant risk to the patient, preclude the patient 
from following and com plet
ing the protocol, or interfere with the 
interpretati on of  safety, efficacy, or PD data .
Alcoho l abuse/r egular consumpt ion is defined as an averag e daily intake of >3
units for males or >2 units for females within 6 mo nths prior to the study .  
One unit is equivalent to 8 g of alcoho l:a half -pint (~240 m L) of beer, 1 glass 
(125 mL) of wine or 1 (25 mL) measure of spirits.
[25] Have had a blood tran sfusio n or severe blood loss within 3 mo nths prior to 
screening or have any hematologic condit ion that may interfere with HbA1c 
measurement ( e.g., hem oglobinopathy , hem olytic anemia, sickle -cell disease) .
[
26]Have fast ing triglycerides >400 mg/dL or non-fasting triglycerides 
>600 mg/dL.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 36[27] Wom en of childbearing potential who
i)are pregnant or intend to become pregnant
ii)are lactating/breast feeding (including the use of a breast pump)
iii)are unwilling to remain abst inent or use birth control as described in
Appendix 4
iv)test posit ive for pregnancy  at the time of screening (Visit 1). Note: a 
urine pregnancy test is conducted at Visit 3.
Prior/Concomitant Therapy
[
28]Are taking drugs that may significantly affect glycemic control ( e.g., niacin 
[allowed if <1. 0g/day ], bile acid sequestrants) .
[
29]Are receiving chronic (last ing longer than 14consecutive days) systemic 
glucocorti coid therapy (including intravenous, intramuscular , 
SC, and oral) or 
intra-articular (but excluding topical, intraocular, intranasal, and inhaled 
preparati ons), or have received such therapy  within 4weeks immediately prior 
to screening with the except ion of replacement therapy  for adrenal  
insufficiency.
[30] Are current ly taking or have taken within the 3 months preceding screening, 
prescription or over -the
-counter medicat ions to promote weight loss.  Patients 
who participate must agree not to init iate a diet and/or exercise program 
during the study  with the intent of reducing body  weight other than the 
lifest yle and dietary measures fo r diabetes treatm ent.
[31] Are taking total daily dose of insulin >100 Unit s at the time of screening.
[
32]Are receiving any oral or injectable medicat ion intended for the treatment of 
diabetes m ellitus other than rapi d-acting and basal analog insulin in MDI in 
the 90 days prior to screening.
[
33]Are using or have used blood pressure -lowering medicat ion at a dose that has 
not been stable for 1 month prior to screening .
Prior/Concurrent Clinical Trial Experience
[34] Are current ly enrolled in any other cli nical study  involving an IP or any other 
type of medical research judged not to be scient ifically or medically  
compatible with this study
.
[35] H ave part icipated, within the las t 30 days in a clinical  trial invo lving an IP. If 
the previous IPhas a long h alf-life, 3 months or 5 half -lives (whichever is 
longer) should have passed .
[
36] Have previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ing LY3209590.  
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 37Other Exclusions
[37] A re invest igator site personnel directly affiliated with this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[
38] Are Lilly  empl oyees.
5.3. Lifestyle Considerations
Per the Schedule of Act ivities (Secti on 1.3), qualified medical staff will provide diabetes
management counseling, which will include instructions on diet and exercise and educat ion 
about the signs, symptoms, and treatm ent of hypoglycemia, should it occur. 
Prescri ption or over the counter (OTC) medications that promote weight loss are exclusionary if 
used wi thin 3 m onths prior to screening (study  entry), or between screening and rando mization.  
These medicat ions are also not allowed at any  time during the treatment period.  If started after 
rando mizat ion, the se medicat ionsshoul d be immedi ately wi thdrawn.  
Study  parti cipants shoul d be instructed not to donate blood or blood products duri ng the stud y or 
for 4 weeks fo llowing the study .
5.3.1. Meals and Dietary Restrictions
Patients shoul d cont inue their usual exercise habits and generally fo llow a healthymeal plan 
(with consistent meal size and time of day )throughout the course of the study . Dietary  
counseling may be reviewed throughout the study , as needed.
In addit ion, pati ents shoul d not receive an intensive diet/exercise program wit h the intent of 
reducing body  weight at any  time during the study , other than the lifest yle and dietary measu res 
for diabetes treatm ent.
5.4. Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but are 
not subsequently randomly  assigned to study  intervent ion.  A minimal set of screen failure 
inform ation is requi red to ensure transparent reporting of screen failure participants to meet the 
Conso lidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authori ties. Minimal information includes demography, 
screen failure details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened once . The interval between screening and rescreening should be at least 4 weeks. A
new ICF must be signed at the time of rescreening andthe study  parti cipant will be assigned a 
new ident ification number. A single r epeat t esting of suspected erroneous/ spurious central 
laboratory resul ts is allowed without rescreening the study  parti cipant.
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 3 8 6. St u d y I nter ve nti o n 
St u d y  i nt er ve nt i o n is defi ne d as a n y i n vest i gat i o nal i nt er ve nt i o n(s), m ar kete d pr o d uct(s), 
pl ace b o ,or m e dical de vice (s) i nt e n de d t o be a d mi nistere d t o a st u d y  p arti ci pa nt acc or di n g t o t he 
st u d y  pr ot oc ol .
6. 1. St u d y I nter ve nti o n(s) A d mi nister e d 
L Y 3 2 0 9 5 9 0 will be pr o vi de d i n a 2 0 m g vial of l y o p hilize d p o w der.  U p o n rec o nstit uti o n per t he 
p har mac y i nstr ucti o ns pr o vi de d b y  t he s p o ns or, L Y 3 2 0 9 5 9 0 will be a d mi nistere d o nce wee kl y as 
S C i nject i o ns.  Eac h patie nt will recei ve 1 i nject i o n eac h wee k, as descri be d i n t he “ Treat me nt  
Re gi me ns” ta ble bel o w.  S C i nject i o ns of L Y 3 2 0 9 5 9 0 will be a d mi nistere d r otati n g bet wee n left 
a n d ri g ht a b d o mi nal  r e gi o n s, a n d u p per a n d l o wer q ua dra nts.  Refer t o St u d y Peri o d 2 i n 
Secti o n 4. 1. 1 f o r details o n h o w I P will be a d mi nistere d. 
P ati e nts will  recei ve treat m e nt wi t h  L Y 3 2 0 9 5 9 0 b y  a n al g ori t h m descri be d i n Secti o n 1 0. 8 .
T he L Y 3 2 0 9 5 9 0 Al g ori t h m  1 is a pa per -base d al g orit h m t hat uses si milar pri nci pals t o t he 
esta blis he d Ri d dle al g orit h m. 
I ns uli n de gl u d ec will use t he esta blis he d Ri d dle al g orit h m a n d is a pa per- base d al gori t h m .
A p pr o xi matel y  o ne -half of  t he s u bjects will be ra n d o mize d i n eac h of  t he 2 re mai ni n g treat me nt 
ar m s.
I ns uli n d e gl u dec will be pr o vi de d as 1 0 0 u nits/ m L i n a prefille d pe n .  It will be a d mi nistere d 
o nce dail y  at a p pr o xi matel y  t he sa me t i me of da y, r otati n g bet wee n left a n d ri g ht a b d o mi nal 
r e gi o ns, a n d u p per a n d l o wer q ua dra nts. 
See Secti o n 6. 7. 1 f o r tra nsit i o ni n g t o treat me nt after st u d y  c o m plet i o n. 
Tre at me nt Re gi me ns 
Re gi me n D ose 
R a n d o miz ati o n t hr o u g h Wee k 2 6 
L Y D ose Al g orit h m 1 
(pa per )L Y i njecti o n 
I ns uli n de gl u dec i ns uli n de gl u dec i njecti o n ( o pe n -la bel) 
A b bre viati o ns:  L Y = L Y 3 2 0 9 5 9 0 .C CI 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 39The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use and reconstitution of the invest igational agent(s) to the 
patient 
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion
at the end of the study  returning all unused medication to Lilly , or i ts desi gnee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroy ed 
by the site, as allowed by local law
Clinical study materials will be labeled according to the country ’s regul atory  requi rements.
6.1.1. Selection and Timing of Doses
For pati ents randomly  assigned to LY3209590 , aloading dose will be determined using T able 1
in Algori thm 1(see Section10.8). The weekly dose adjust ment thereafter will be based on 
guidance provi ded in Secti on10.8.  The doses will be administered at approximately the same 
time and day  each week .  The actual  date, time and dose of each dose administrati ons
(LY3209590 and insulin degludec) will be recorded in the participant ’s diary  (and parti cipant’s 
medical record when administered at the site).
If a patient misses a scheduled dose of LY3209590, it should be administered a soon as possible, 
but no l ater than 3 days after the scheduled administration.  If more than 3 day s have elapsed 
since the scheduled administration, the dose should be skipped and the next inject ion will occur 
at the next scheduled day  and time.
Insulin degludec should be administered a t the same time each day  adjusted per the m odified 
Riddle algori thm (Secti on 10.8). 
Patients who miss a dose of insulin degludec should inject their daily dose during waking hours 
upon discovering the missed dose.  Instruct patients to ensure that at least 8 hours have elapsed 
between consecut ive insulin degludec inject ions (Tresiba ®USPI).
For details on the titration algorithms to be used, refer to S ection 10.8.
6.1.2. Special Treatment Considerations 
6.1.2.1. Standards of Medical Care
Invest igators and other study  team  members are expected to treat patients according to the 
nationally established standards of care for diabetes management in respect ive participat ing 
countri es, except where that treatment would be in conflict with the pro tocol -provi ded treatm ent 
requi rements. If there are no local standards of care for diabetes, the invest igators should fo llow 
current published standards of care from the American Diabetes Association (2016) and the 
European Associat ion for Study  of Diabet es (Inzucchi et al. 2015) during their patients’ 
participat ion in this study . Standards of prevent ion of persistent hyperglycemia and ketone 
monitoring must be followed during the course of the study  to prevent DKA.
Patients will  cont inue their short acting insulin treatment throughout the duration of the study. 
Invest igators are responsible to adapt mealt ime and correction bo lus dosing according to 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 40standards of medical care. When t itrating basal insulin a reduct ionof the m ealtime insulin is 
necessary  in most cases and should be considered by invest igators to prevent hypoglycemia.
This sect ion provi des gui dance on management of episodes of hypoglycemic events and events 
ofsevere, persistent hy perglycemia. For effect ive implementation of measures described here, it 
is important that patients, and their caregivers, if applicable, be well -educated about the signs 
and symptoms of hyperglycemia ( e.g., severe thirst, dry  mouth, f requent micturit ion, or dry  skin) 
and hypo glycemia ( e.g., intense hunger, sweat ing, tremor, restlessness, irritabilit y, depressio n, 
headaches, disturbed sleep, or transient neurological disorders). Patients should be instructed to 
contact the invest igative site in the event of severe, persistent hyperglycemia or severe 
hypoglycemia between study  visits.
6.1.2.2. Management of Increased Hypoglycemia Risk
To date, effects of LY3209590 on hypoglycemia in patients with T2DM are not different as 
compared to other basal insulins. An object ive of the study  is toassess the risk of hypoglycemia 
in T1DM patients receiving LY3209590 as co mpared to insulin degludec.
In this study , increased risk o f hypoglycemia is defined as having a single episode of severe 
hypoglycemia or having more than 1 epi sode of docum ented hypoglycemia with BG <54 mg/dL 
within a 1- week peri od at any  time during the treatment period . Documented hypoglycemia is 
defined as any  time a participant reports a SMBG ≤70 m g/dL (<3.9 mmo l/L)or any  invest igator 
confirmed case of severe hypoglycemia .  
In cases where a patient experiences hypoglycemia as described above, to confirm the increased 
risk, the study  sites must ensure that the pati
ent has been fully co mpliant with the assigned 
therapeuti c regimen and also that there is no evidence of other possible causes of hypoglycemia 
(e.g., omission o f meal , inadequate m eal or correctio n bolus, unexpected increase in exercise) .
Patients fulfilling the definit ion of increased risk of hypoglycemia should first correct their bo lus 
dosing, then decrease their dose of IP per the respective dosing algorithm, fo llowed by 
discontinuat ion of IP, if needed.  
6.1.2.3. Management of Patients with Severe, Persistent Hyperglycemia during the 
Treatment Period
Transient hy perglycemia may be observed during the first 1to 2weeks of treatment with 
LY3209590 and addit ional correction doses of rapid acting insulin may be used to manage 
hyperglycemia during this transit ion peri od.
An addit ional therapeut ic intervent ion shoul d be consi dered in patients who develop severe, 
persistent hy perglycemia after randomization based on the following criteria (FDA 2008):
a)average fasting glucose ( FG)>270 mg/dL (>15.0 mmol/L) over any 2- week peri od or 
longer during the first 6 weeks postrandomizat ion; or
b)average FG >240 mg/dL (>13.3 mmo l/L) over any 2 -week period or longer fro m Week 6 
to Week 12 postrandomizat ion; or
c)average FG >200 mg/dL (>11.1 mmo l/L) over any 2 -week period or longer after Week 
12.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 41Invest igators should first confirm that the patient doe s not have an acute condit ion causing severe 
hyperglycemia ,and after the first 12 weeks of the study , that the patient i s fully com pliant wi th 
the assigned therapeutic regimen.  The invest igator will decide, in consultat ion with the patient, 
on an appropr iate intensification of insulin therapy after consi dering rel evant clinical criteria.  
Patients who receive a new intervent ion for hyperglycemia management should also continue 
administering IP for the remaining period in the trial.
6.1.3. Medical Devices
The spo nsor will provide syringes for subcutaneous inject ion.
6.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are reported 
and reso lved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion and only authorized site 
staff may supply or administer study  intervent ion. All study  intervent ion must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the l abeled storage conditions with access limited to the invest igator and authorized site 
staff.
The invest igator, institution, or the head of t he medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance (i .e., 
recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons will be
provi ded by the sponsor.
The study  site must store all study  intervent ion in a locked and secure environment.  
Invest igators should consult the study drug information provided in the Pharmacy Instructi onsor 
label f or the specific administration information (including warnings ). 
6.3. Measures to Minimize Bias: Randomization and Blinding
This is an open -label study; thus, it will be unblinded.  H owever, the specific intervent ion to be 
taken by  a parti cipant will be assig ned using an Interactive Web Response System ( IWRS ). The
site will  contact the IWRS pri or to the start of study  intervent ion administration for each 
participant. The site will record the intervent ion assignment in the appropriate data capture tool .  
Potential bias will be reduced by  the f ollowing steps: central rando mizat ion, stratificat ion, 
blinded adjudicat ion for CV endpoints.
Patients who m eet all cri teria for enrollment will be randomized to treatment at Visit 3.  
Assignment to treatment groups will be determined by a co mputer -generated random sequence 
using theIWRS.  The IWRS will be used to assign IP to each patient.  Site personnel will 
confirm that they  have l ocated the correct IP by  entering a confirmat ion number found on the IP 
label into the IWRS.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 42To achieve between -group com parabilit y for site factor, th e randomizat ion will be stratified by  
baseline HbA1c (<8.5%, ≥8.5%), and country .  The randomization scheme will be performed 
using IWRS ,which will ensure balance between treatment groups.
6.4. Study Intervention Compliance
The assessment of treatment complian ce wi th IP (LY3209590 or insulin degludec) will be 
determined by the fo llowing:
Inform ation about the once weekly IP inject ions administered at home by  the pat ient will 
be entered into the patient diary  by the pat ient and reviewed by  the si te personnel at each 
study  visit; this inform ation will be co llected in the electronic study  diary ;
IP accoun tabilit y will be checked according to the Schedule of Act ivities (Secti on 1.3).  
Study  parti cipants will be instructed to return all dispensed vials, any unused pens,and/or 
all empty  cartons at the next visit to the study  site for the purpose of performing drug 
accountabilit y.  
Other aspects of compliance wi ll also be assessed at each visit, including the patient’s adherence 
to the visit schedule, co mpliance with the concomitant short acting insulin requirements and 
other m edicati on guidances (Secti on6.5), com pletion of study  diari es, resul ts of SMBG through
CGM, and any  other parameters the invest igator considers necessary .  Pati ents consi dered to be 
poorly  com pliant wi th their medicat ions and/or study  procedures ( e.g., missed visits or specific 
diagnosti c tests) will  receive addi tional training and instruct ions, as requi red.
When participants are dosed at the site, they  will receive IPdirect ly from  the invest igator or 
designee, under medical supervisio n.  The date and time of each dose administered in the clinic 
will be recorded in the source documents and recorded in the diary.  
When participants administer study  treatm entat home, compliance wit h study  treatm entwill be 
assessed at each visit. Compliance will be assessed by  direct questi oning, reviewing eCOA 
docum entati on,counting returned pens, etc. during the site visit s.
A record of the number of the pens and study  medicati onsdispensed to and taken by  each 
participant m ust be m aintained and reconciled wit h study  intervent ion and compliance records.  
Intervention start and stop dates, including dates for intervent ion delays and/or dose reductions 
will also be recorded in the electroni c case report form  (eCRF)
.
6.5. Concomitant Therapy
Any medicat ion or vaccine (including OTC or prescript ion medicines, vitamins, and/or herbal 
supplements) or other specific c ategories of interest) that the participant is receiving at the time 
of enro llment or receives during the study  must be recorded in the eCRF along with:
Reason for use
Dates of administration including start and end dates , and
Dosage information including dose and frequency for concomitant therapy  of special  
interest.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 43Lilly Medical shoul d be contacted if there are any  questi ons regarding concomitant or prior 
therapy .
Parti cipants will be permitted to use concomitant medicat ions that they  requi re during the study , 
except prohibited medicat ions described in Secti on 5.2 and Sections 6.5.1 and 6.5.2 below.   In 
addition, certain permitted medicat ions (e.g., treatments for blood pressure or dyslipidemia) 
described in Section s6.5.3 and 6.5.4 should be cont inued, but not changed, during the study.
Parti cipants will co ntinue to use concomitant short- acting insulin throughout the treatment 
period.  Discont inuat ion or changes to regimen are not permitted, except in situat ions where dose 
adjustm ent is requi red for medical  reasons or when allowed per study  protocol . 
Inves tigative site staff will inform pat ients that they must consult with the investigator or a 
designated site staff member upon being prescribed any new medicat ions during the study , 
except when init iated for treatm ent of m edical  emergencies.  
Non-study  medications taken by pat ients who are screened but not randomized will not be 
reported to Lilly  unless an SAE or AE occurs that the invest igator believes may have been 
caused by  a study  procedure.
6.5.1. Medications that Promote Weight Loss
Prescri ption or OTC medica tions that prom ote weight l oss are excl usionary if used wi thin the 
3months pri or to screening, or any  time after screening (see Section 6.5).  If started after 
screening, these medicat ions should be stopped immediately.  In addit ion, pati ents shoul d not 
receive an intensive diet/exercise program with the intent of reducing body  weight at any  time 
during the study , other than the lifest yle and dietary  measures for di abetes treatm ent (see 
Secti on5.3).
6.5.2. Systemic Glucocorticoids
Chronic systemic glucocortico id therapy (excluding to pical, intra ocular, intranasal , or i nhaled 
preparati ons) is exclusio nary if used >14 consecut ive days during the 1- month peri od before 
screening or between screening and rando mizat ion at Visit 3.  
Patients treated with these medicat ions after randomizat ion will be ex cluded from the efficacy  
evaluable populat ion for analyses if they receive: 
>14 day s consecut ive days of therapy, or
More than 1 course of therapy  during the study .
6.5.3. Antihypertensive Medications
If used, anti -hypertensive therapy  should be kept stable thr oughout the trial to allow assessments
of the effect of rando mized therapies on blood pressure . 
6.5.4. Dyslipidemia Medication
If used, dyslipidemia therapy shoul d be kept stable throughout the tri al to all ow assessments of 
the effect of rando mized therapies on lipid endpo ints. 
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 4 4 6. 6. D ose M o dific ati o n 
D osi n g of  basal  i ns uli n will  b e i n di vi d ualize d base d o n F G.  See Secti o n 1 0. 8 f o r details o f d ose 
m o dificati o n. 
6. 7. I nter ve nti o n after t he E n d of t he St u d y 
After t he e n d of t he treat me nt peri o d patie nts s h o ul d c o nti n ue t o m o nit or t heir F G le vels.  T he 
treati n g p h ysicia n s h o ul d t he n ma ke t he decisi o n base d o n l ocal cli nical pract ice, if a n d w hat 
a d di ti o nal  a n ti h y per gl yce mic treat me nt nee ds t o be a d mi nistere d. 
I n vest i gat i o nal pr o d uct will n ot be m a de a vaila ble t o patie nts after c o ncl usi o n of t he st u d y .  After 
I P i s disc o nt i n ue d, a n a p pr o priate dia betes treat me nt re gi me n will be i nit iate d b y  t he i n vesti g at or. 
6. 7. 1. Tre at me nt after St u d y C o m pleti o n 
T he l ast st u d y  tr e at m e nt a d mi nistrati o n f or patie nts treate d wit h L Y 3 2 0 9 5 9 0 will be at Wee k 2 5 
a n d f or pati e nts treate d wit h i ns uli n de gl u dec t he e ve ni n g bef ore t he last st u d y  visit at Wee k 2 6 .  
T he was h o ut of L Y 3 2 0 9 5 9 0 ma y ta ke u p t o 1 0 wee ks t o c o m plete. A n y a p pr o priate basal i ns uli n 
treat m e nt m ust t heref ore be i nst it ut e d sl o wl y a n d u n der re g ular s u per visi o n of B G pr ofiles after 
di sc o nti n uat i o n of L Y 3 2 0 9 5 9 0 . Si nce 
 
  T heref ore, a sl o w u p -ti tr ati o n of  a n ot her basal 
i ns uli n is necessar y  t o pre ve nt h y p o gl yce mia d ue t o o verla p pi n g i ns uli n act i o n. F or e xa m ple, n o 
i ns uli n w o ul d be re q uire d u nt il t he st u d y partici pa nt’s F G i ncreases t o > 1 0 0 m g/ d L, a n d t he n 
dail y  basal i ns uli n w o ul d be i ni ti ate d a n d a dj uste d base d o n F G. 
St u d y  p arti ci pa nts assi g ne d t o t h e i ns uli n de gl u dec treat me nt gr o u p will s witc h t o t he basal 
i ns uli n use d bef ore e nteri n g t he st u d y . If i ns uli n de gl u dec was t he pre -st u d y  basal  i ns uli n, t he y  
ca n c o nt i n ue wit h t he sa me d ose use d u nt il Visit 2 0 of t he st u d y .  If  t h e y  s wi tc h t o a n ot her ba sal  
i ns uli n (e. g., i ns uli n glar gi ne), st u d y  p arti ci pa nts s h o ul d i nject a dail y  d ose, w hic h is 2 0 % l o wer 
t h a n t he last d ose of i ns uli n de gl u dec use d bef ore Visit 2 0 a n d t it rate u n der s u per visi o n of t he 
i n vesti gat or usi n g t he c o u ntr y -s pecific l a bel f or t heir pre -st u d y  basal i ns uli n. C CI 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 457. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention
Study  drug m ay be perm anently discont inued or temporarily wit hheld during the study .  
Parti cipants who perm anently discont inue study  drug early will undergo ETprocedures, which 
include
an ETvisit or,
post-treatm ent follow-up visits ( ED 1, ED 2 ).
The invest igator will co mplete any  AE reporting and necessary  follow-up.
7.1.1.
Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of invest igational product include, but are 
not limited to :
Participant d ecision
othe patient or the pati ent’s designee, for example, parents or legal guardian 
requests to discont inue IP.
Hepat ic event or liver test abnormality :Participants who are discontinued from IPdue 
to a hepatic event or liver test abnormalit y shoul d have addi tional hepatic safety  data 
collected via eCRF
Discontinuati on of  the IPfor abnormal liver tests should be considered by the 
investigator when a participant meets one of the following condit ions after consultation 
with Lilly  Medical
oALT or AST >8 xULN
oALT or AST >5X ULN for more than 2 weeks
oALT or AST >3X ULN and TBL >2X ULN or internat ional norm alized 
ratio (INR) >1.5
oALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
oALP >3X ULN
oALP >2.5X ULN and TBL >2X ULN
oALP >2.5X ULN with the appearance of fatigu e, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, participants will be discont inued fro m the IPin the fo llowing ci rcumstances:
If a patient i s inadvertent ly enro lled and it is determined that cont inued treatment with IP 
woul d not be medically  appropri ate (see Section 7.2.1 )
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 46if a pat ient is di agnosed wi th an act ive or untreated malignancy (other than basal or 
squamous cell skin cancer, in situ carcino mas of the cervix, or in situ prostate cancer) 
after randomizat ion
if the invest igator or sponsor decides that the patient should be withdrawn from IP; if the 
investigator decides to permanent ly disc ontinue IP because of an SAE or a clinically 
significant laboratory  value, Lilly  or its designee shoul d be al erted immediately
if the invest igator, after consultation with Lilly Medi cal, determines that a systemic
hypersensit ivity react ion has occurred related to study  drug administration, the participant 
shoul d be perm anent lydiscont inuedfrom IP.
See the Schedule o f Activities(Secti on 1.3)for data to be collected at the time of intervent ion 
discontinuat ion and fo llow-up and for any  further evaluat ions that need to be completed.
Patients who stop the IPpermanent ly may receive another glucose -lowering intervent ion, if 
appropriate, and will cont inue participat ingin the trial according to the protocol to collect all 
planned efficacy  and safet y measurements.
7.1.2. Temporary Discontinuation
In certain situat ions after rando mizat ion, the investigator may need to temporarily discont inue 
(interrupt) IP(e.g., due to an AE or a clinically significant laboratory  value). The m aximum  time 
allowed for a temporary  interruption of IP is 14 days. If IPinterruption is due to an AE, the 
event i s to be docum ented and fo llowed according to the procedures in Secti on 8.3ofthis 
protocol .  Invest igators should inform the sponsor that IPhas been temporarily interrupted.  
Every  effort shoul d be made by  the invest igator to maintain patients on IPand to restart IPafter 
any tem porary  interrupti on, as soon as i t is safe to do so.  The data related to temporary  
interrupti on of  IPand use of non-study  insulin will be documented in source doc uments and 
entered in the eCRF.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant will be discont inued ( withdraw n)from the study in the fo llowing ci rcumstances: 
if he or she is diagnose d with any type of diabetes mellitus other than T1DM
at any  time at his/her own request 
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during the study  
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
investigator decisio n
othe invest igator decides that the participant should be discont inued from 
the study
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 47oif the participant, for any  reason , requi res treatm ent wi th another 
therapeuti c agent that has been demo nstrated to be effect ive for treatm ent 
of the study  indicati on, discont inuat ion from the study  occurs pri or to 
introducti on of  the new agent
participant deci sion:
othe patient or the pati ent’s designee, for example, parents or legal guardian 
requests to be withdrawn fro m the study
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as show n in the Schedule of Act ivities(Secti on 1.3). See Schedule of Activit iesfor 
data to be collected at the time of study  discont inuation and fo llow-up and for any  further 
evaluat ions that need to be completed .  The participant will be permanently discont inued both 
from the study  intervent ionand fro m the study  at that time .
If the participant withdraws consent for disclosure of future informat ion, the sponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent.   If a participant 
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested, 
and the invest igator must document this in the s ite study  records.
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  treatm ent unl ess 
there are extenuating circumstances that make it medically necessary for the participant to 
continue on study  treatm ent.  If the invest igator and the sponsor clinical research physician 
(CRP )agree it is m edically appropriate to continue, the invest igator must obtain documented 
approval  from the sponsor CRP to allow the inadvertently  enrolled parti cipant to continue in the 
study  with or wi thout treatm ent wi th IP. Safet y follow up i s as outlined in Sect ion 1.3(Schedule 
of Activities), Section 8.3(Adverse Events and Serious Adverse Events), and Section 8.2(Safet y 
Assessments) of the protocol.
7.3. Lost to Follow up
A study  participant will be considered lost to follo w-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.
The fo llowing acti ons m ust be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or s hould continue in 
the study .
Before a participant is deemed lost to f ollow-up, the invest igator or designee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls and, 
if necessary , a certified l etter to the parti cipant’s last known mailing address or local 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 48equivalent m ethods). These contact attempts should be documented in the participant’s 
medical record.
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Secti on10.1.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 498. Study Assessments and Procedures
Study  procedures and the study  visit s at whi ch they  are perform ed, including tolerance limits for 
the study  visits, are listed in the Schedule of Act ivities (Sect ion1.3).  Adherence to the study 
design requirements, including those specified in the Schedule of Act ivities, is essent ial and 
requi red forstudy conduct .
Efficacy and safet y assessments included in this study  are generally  regarded as reliable and 
accurate with respect to the efficacy and safet y assessments in individuals and populat ions with 
T1DM .
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Asses sment
The primary  efficacy  measure is HbA1c change from  baseline to Week 26.
8.1.2. Secondary Efficacy Assessments
Secondary  efficacy assessments for this study  are:
• HbA1c change fro m baseline to Week 12
• FGchange from baseline to Weeks 12 and 26
• Bolus insulin dose change fro m baseline to Weeks 12 and 26
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the Schedule o f Activities
(Secti on1.3)
.
The fo llowing safety  assessments will be evaluated as secondary  object ives:  
Incidence and rate of hypoglycemia 
Incidence of treatment -emergent SAEs
Clinical laboratory  assessments wi th specific focus on liver aminotransferase changes
8.2.1. Physical Examinations
A co mplete physical examinat ion will include, at a minimum, assessments of the CV, 
Respiratory , Gastroi ntestinal and Neuro logical systems.  Hei ght and wei ght will  also be 
measured and recorded.
Invest igators should pay special attention to clinical signs related to previous serious illnesses.
Addit ionally , invest igators should inspect inject ion sites during the physical examinat ion.  
8.2.2. Vital Signs
For each participant , vital signs measurements should be conducted according to the Schedule of 
Activities (Section 1.3).
Sitting blood pressure ( BP)and pulse rate will be measured using automated electronic 
sphygmo mano meter according to the Schedule o f Activities (Section 1.3).  Vi tal sign 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 50measurements should be taken before obtaining an ECG tracing and before collect ion of blood 
samples for laboratory  testing, at vi sits where required (see Schedule of Act ivities, Section 1.3).
The parti cipant shoul d be required to sit quiet ly for 5 minutes before vital sign measurements are 
taken.  An appropriately sized cuff (cuff bladder encircling at least 80% of the arm) sho uld be 
used to ensure the accuracy  of BP m easurements.  The arm used for the BP measurement should 
be supported at heart level.  Blood pressure shoul d be m easured consistent ly using the same arm 
throughout the study .  For each parameter (pulse rate, sy stolic BP, and diastolic BP), 3 
measurements will be taken using the same arm; the recordings should be taken at least 1 minute 
apart, and each measurement of sitting pulse rate and BP will be recorded in the eCRF.
8.2.3. Electrocardiograms
For each patient, triplica te 12 -lead digital ECGs and single safet y ECGs will be collected 
according to the Schedule of Act ivities (Secti on 1.3).  Patients must be supine fo r approximately  
5 to 10 minutes before ECG collect ion and rem ain supine but awake during ECG collect ion.
ECGs will be performed prior to collect ion of any  blood sam ples.
ECGs will be interpreted by  a qualified physician ( the invest igator or qualified desi gnee) at the 
site as soon as possible after the time of ECG collection, and ideally while the patient is st ill 
present, to determine whether the patient meets entry  criteria at the relevant visit(s) and for 
immediate patient management should any  clinicall y relevant findings be ident ified.  
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designated by  Lilly .  
The central ECG laboratory  will perf orm a basic quali ty control  check ( e.g., demographics and 
study  details) then store the ECGs in a database.  At a future time, the stored ECG data may be 
overread at the central ECG laboratory  for further evaluat ion of machine -read m easurements or 
to meet regul atory  requi rements.  
The m achine -read ECG intervals and heart rate may  be used for data analysis and report writing 
purposes unless an overread of the ECGs is conducted prior to complet ion of the final study  
report (i n which case the overread data would be used).
8.2.4. Self-monitoring of Blood Glucose (SMBG)
At Visit 2, patients will receive the Dexco m G6CGM device and training on its use, sensor 
placement, interpretation of CGM values and alarms, and the requirements for CGM .  SMBG 
will be performed through th isCGM device. In the receiver of the CGM device 2 alarm settings 
are mandatory :an hypoglycemia alarm at 70mg/dl and a hypoglycemia alarm at 55mg/dl.
Glucose readings shoul d be obtained for monitoring patientsafety (hypoglycemia) and may  be 
checked as frequent ly as necessary .  
Patients should record 6-point glucose profiles in the eDiary
provi ded, prior to the visi ts indicated by  the Schedul e of Activities(Secti on 1.3).  Patients with 
missing eDiary gl ucose entries shoul d be retrai ned on the importance of glucose reporting in the 
eDiary.
Patients willbe instructed to record a prebreakfast (fasting) reading every  morning and to record 
all results in the eDiary .Patients w ill also review BGusing the CGM device as needed to 
evaluate symptoms of hypoglycemia.
Patients willbe instructed to record 6-point glucose profiles over a 24 -hour peri od on 
2nonconsecut ive days during the 7-day period prior to visits indicated in the S chedule o f 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 51Activities (Section 1.3)using their CGM sensor .  The 6-point profile consists of pre -meal and 
2-hour postprandial glucose readings for the m orning, midday , and evening m eals in 1 day .  Pre -
meal measurements should be taken before the patient begins eat ing the meal.  Patients shoul d 
record their glucose measurements in their eDiaries and bring the diary to the invest igative site at 
each study  visit.  
Parti cipants are permi tted to use a personal  glucose m eter for add itional monitoring if deemed 
necessary  or by  personal  choice.  Thi s data, however, should not be used for dosing decisio ns 
within the study as long as the CGM system is functional .In case of technical issues or during 
the calibration period of the CGM sy stem  a personal  BGmeter can be used for therapeutic 
decisio n making.
8.2.5. Clinical Safety Laboratory Assessments
See Secti on10.2 for the list of clinical laboratory  tests to be perform ed and the Schedule of 
Activities(Secti on 1.3)for the timing and frequency .
The invest igator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study  in the AE section of the eCRF. The 
laboratory  reports m ust be filed wit h the source documents. Clinically significant abnormal 
laboratory  findings are those ,which are not associated with the underlying disease, unless judged 
by the investigator to be more severe than expected for the participant's condit ion.
All laboratory  tests wi th values considered clinically  significantly abnorm al during parti cipat ion 
in the study  or wi thin 6 weeks after the l ast dose of study  intervent ion (i.e., within the fo llow up 
period)should be repeated unti l the values return to normal or baseline or are no longer 
considered clinically significant by  the investi gator or Lilly medical.
If such values do not return to normal/baseline wit hin a peri od of  time judged reasonable 
by the investigator, the etio logy should be i dentified and the sponsor notified.
All protocol -requi red laboratory  assessments, as defined in Section10.2, must be 
conducted in accordan ce wi th thelaboratory  manual  and the Schedule of Act ivities.
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are 
considered clinically si gnificant by  the investi gator (e .g., SAE or AE or dose 
modificati on), then the results must be recorded in the eCRF.
8.2.6. Safety Monitoring
The principal invest igator will monitor safet y and laboratory  data throughout the study and 
shoul d discuss s afety concerns wit h the sponsor immediately upon occurrence or awareness of 
the concern to determine whether the participant should continue or discontinue study  drug .
8.2.6.1. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, ALP ≥2X U LN, or el evated TBL ≥2X 
ULN, liver testing ( Secti on10.5) shoul d be repeated within 3 to 5 days including ALT, AST, 
ALP, TBL, direct bilirubin, gamma -glutamyl  transferase, and creat ine kinase to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 52worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator and in 
consultatio n with the study  Lilly  Medical .  Moni toring of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels. 
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if 1 or more of the fo llowing condi tions 
occur: 
elevation of ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated TBL to ≥2X ULN (except for cases of known Gilbert’s syndro me)
elevation of ALP to ≥2X ULN on 2 or more consecutive blood tests
patient discont inued fro m treatm ent due to a hepatic event or abnormalit y of 
liver tests
hepat ic event considered to be a SAE
8.2.7. Body Weight
Body  weight will be m easured at prespecified t ime points (see Sche dule of  Activities, 
Secti on1.3).  Patients will  be weighed in a light hospital gown or standard clinical research site 
scrubs at approximately  the same t ime in the morning after an overnight fast and after evacuat ion 
of bowel  and bladder contents, if possible.  
Weight will be measured once at screening (non -fasting) and recorded in the source document 
and eCRF.  At lead- in and rando mizat ion (Visit 2 and Visit 3, respectively) and all subsequent 
visits indicated in the Schedule of Act ivities (Section 1.3), weight will be measured twice, with 
the pati ent stepping off the scale between measurements.  
Both wei ght m easurements will be recorded in the source document and the eCRF.  Calibrated 
(within 6 m onths pri or to study  start) scal es shoul d be used.  The same scale should be used for 
all weight m easurements throughout the study  and shoul d not be m oved during the conduct of 
the study .
8.3. Adverse Events and Serious Adverse Events
All AEswill be reported by  the parti cipant (or, when appropriate, by  a caregiver, surrogate, or 
the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events t hat meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, are considered related to the study  intervent ion or study  procedures, or 
that caused the participant to discontinue the study intervent ion or the study  (see Secti on 7).
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 53The SAE reporting to spons or begins after the patient has signed the ICF and has received study  
drug.  However, if an SAE occurs after signing the ICF, but prior to receiving LY3209590, it 
needs to be reported ONLY if it is considered reasonably possibly related to study  procedures .
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Secti on10.3. The invest igator will 
submit any  updated SAE data to the sponsor within 24 hours of i t being available.   
Invest igators are not obligated to actively seek AE or SAE after conclusio n of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the preferred m ethod to i nquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/ contacts .All SAEs, and AEs of special interest (as defined in Sect ion 8.3.7 ), 
will be fo llowed unt il resolut ion, stabilizat ion, the event is otherwise explained, or the participant 
is lost to follow -up (as defined in Sect ion7.3). Further informat ion on follow- up procedures is 
provi dedin Section10.3.
8.3.4. Regula tory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and invest igators.
Invest igator safet y reports must be prepared for suspected unexpected serio us adverse react ions 
(SUSAR) according to local regulatory  requi rements and sponsor policy  and f orwarded to 
investigators as necessary .
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informat ion (e.g., summary or list ing of SAEs) from the sponsor will review and then file 
it along wi th the IBand will notify the IRB/IEC, if appropriate according to local requirements.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 548.3.5. Pregnancy
Pregnancy (maternal or paternal exposure to IP) does not meet the d efinit ion of an AE.  
However, to fulfill regulatory  requi rements, any pregnancy  should be reported following the 
SAE process described in Section10.4 and to collect data on the outcome for both mother and 
fetus.
Details o f all pregnancies in female participants and, if indicated, female partners of male 
participants will be co llected after the start of study intervent ion and unt il 90 days after the l ast 
dose.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Section10.4.
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
8.3.6.
Cardiovascular Events
Deaths and nonfatal CV AEs will be adjudicated by a committee of physicians external to Lilly 
with cardi ology expertise.  The nonfatal CV AEs to be adjudicated include:  myocardial  
infarction ; hospi talizat ion for unstable angina; hospitalizat ion for heart failure; coronary  
intervent ions (such as coronary  artery  bypass graft or percutaneous coronary  intervent ion); and 
cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic 
attack.
8.3.7. Adverse Events of Special Interest 
Adverse events of special interest (AESIs) for this program include:
a.Hypoglycemia
b.Allergic/hypersensit ivity react ions
If any o f these AESIs are reported, sites will be prompted to collect additional details/data.
8.3.7.1. Hypoglycemia
Patients will  collect inform ation on episodes of hypoglycemia starting from Visit 2 unt il the last 
study  visit (Visi t 801 or ET vi sit).  For that purpose, pati ents will  be trained about si gns and 
symptoms of hypoglycemia, how to treat hy poglycemia, and how to collect in study  diaries 
appropri ate inform ation for each episode of hypoglycemia according to the Schedule of 
Activities (Section 1.3).  
Parti cipants will be instructed to report hypoglycemia in the eDiary any time he/she experiences 
signs or symptom s of hypoglycemia with or without a SMBG ≤70 mg/dL (<3.9 mmo l/L).
Severe hypoglycemia is defined as an event requi ring assistance o f another person to actively  
administer carbohydrate, glucagon, or other resuscitat ive act ions.  During these episodes, the 
participant has an altered mental status and cannot assist in his/her own care, may be
semico nscious or unconscious, or experience co ma with or wi thout sei zures and may  requi re 
parenter al therapy .  Glucose measurements may not be available during such an event, but 
neuro logical recovery  attributable to the restoration of BGconcentrati on to norm al is considered 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 55sufficient evidence that the event was induced by a low BGconcentration ( ≤70mg/dL [ <3.9 
mmo l/L]). 
If a hypoglycemic event meets the criteria of severe as confirmed by the invest igator , it needs to 
be recorded as serious on the AE eCRF and reported to Lilly as an SAE.
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly 
categori zed, the effect of the intervention be assessed, and the frequency and durati on of 
hypoglycemia be evaluated.  The role of dietary  changes and physical exercise (or any  other 
contributing factor) in the development of an event should be established.  The patient should 
receive addit ional educat ion, if deemed appropriate.   Management of increased risk of 
hypoglycemia is described in Section 6.1.2.2 .
8.3.7.2. Allergic/Hypersensitivity Reactions
All allergic or hy persensi tivity react ions, including injection site react ions (ISR), will be reported 
by the investig ator as ei ther AEs or, if any serious criterion is met, as SAEs.  Symptoms of a 
localISRmay include ery thema, indurat ion, pain, pruritus, and edema.  If an inject ion site event 
is reported, the AE will be recorded, and additional data will be provided to the sponsor in the 
eCRF.
Addit ional data, such as ty pe of react ion and treatment received, will be co llected on any AEs or 
SAEs that the invest igator deems related to IPvia an eCRF created for this purpose.  IPshould 
be tem porarily  interrupted in any  individual suspected of having a severe or serious allergic 
reacti on to IP(Secti on7.1.2 ).  IPmay be resta rted when/if it is safe to do so, in the opinio n of the 
investigator.  If IPis permanent ly discont inued, see Secti on7.1.1 for procedures required in this 
situation.
If an ISR is reported, the informat ion will be provided to the sponsor in the eCRF.  If criteria for 
a SAE are met, the invest igator will also complete the SAE form and urgently report the SAE.
8.3.7.3. Systemic Hypersensitivity Reactions 
Many  drugs, but parti cularly biologic agents ,carry the ri sk of systemic hypersensit ivity 
reacti ons. If such a react ion occurs, a dditional data describing each symptom should be provide d
to the sponsor in the eCRF .  
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving study  drug . It is recommended that participants
who experience a systemic hypersensit ivityreact ion be treated per the local standard of care .  
In the case of generalized urticaria oranaphylaxis ,additional samples shoul d be collected as 
described in Appendix 9 (Reco mmended Laboratory  Testing for Hy persensi tivity Events ). 
Laboratory  resul ts are provi ded to the sponsor v ia the central laboratory .
8.3.8. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges a deficiency
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effectiveness, or performance of a 
Lilly product after it is released for distribut ion.When the abilit y to use the product safely is 
impacted, the fo llowing are also product complaints: 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 56a.Deficiencies in labeling informat ion, and
b.Use errors for device or combinat ion products due to ergonomic design elements of the 
product.
Sponsor collects product complaints on investi gational  products, m edical devices, and drug 
delivery  systems used in clinical studies in order to ensure the safety  of study  participants, 
monitor qualit y, and to facilitate process and product improvements.
Com plaint sare al so collected on comparators and other materials supplied, as required and 
instructed for the study .
Parti cipants will be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product, medical device ,or delivery system, so 
that the situation can be assessed.
Product complaints will be reported by  the invest igator to the sponsor per instructions provided 
on the study  specific Product Complaint Form.
With each co mplaint related to a medical device or delivery  system , the invest igator will assess 
and indicate on the complaint form whether the product complaint could have l ed to an SAE had 
precauti ons not been taken.
8.4. Treatment of Overdose
In the case of an accidental  overdose, contact the sponsor in regards to patient management. 
For pati ents wi th suspected or confirmed overdose ofLY3209590, there is no specific antidote.  
The participant shoul d monitor or be monitored for hypoglycemia.  Treatment is supportive, 
depending on the participant’s symptoms. The management of hypoglycemia should take into 
account the long duration o f action of  LY3209590, and if there is any  concern regarding 
sustained glucose monitoring or nutrient access, the invest igative staff should consider imposing 
close m edical  monitoring (e.g., hospi talizat ion
).  
In the event of an overdose with insulin degludec, refer to the Product Label.
8.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 1.3),venous blood 
samples will be co llected to determine the plasma concentrations of LY3209590.  After Visit 3, 
PK samples can be taken at any time during the visit.  Note:  PK sample co llection is not 
intended for p articipant s rando mized to insulin degludec treatment.
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.   
The actual  date and time (24- hour clock time) of each sampling will be recorded.
All the samples will be analyzed at a laboratory  designated by the sponsor and sto red at a facilit y 
designated by  the sponsor . 
Plasma concentrations o f LY3209590 will ut ilize a validated enzyme -linked immunosorbent 
assay (ELISA) method.  
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 57Bioanaly tical samples collected to m easure IP concentration will be retained for a maximum of 
1year fo llowing last pati ent visi t for the study .
8.6. Pharmacodynamics
In addit ion to PD parameters discussed in the efficacy  and safet y sections, fast ing free fatty  acids 
(FFA) and triglycerides will be evaluated as PD biomarkers of lipo lysis, which is a sensi tive 
measure of peripheral insulin act ivity.
Samples co llected to measure FFA will be ident ified by the pat ient number (coded) and retained 
at a facilit y selected by  Lilly  or its desi gnee f or a maximum  of 2 years fo llowing last pati ent visi t 
for the stud y at a facilit y selected by Lilly  or its desi gnee.
8.7. Genetics
A blood sam ple for deoxyribonucleic acid (DNA )isolation will be co llected fro m participants. 
See Secti on10.7 for informat ion regarding genet ic research and Secti on10.1.7 for details about 
sample retention and custody .
8.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical st udies to enable examinat ion of 
these quest ions through measurement of bio molecul es including DNA , 
ribonucleic acid, 
proteins, lipids, and other cellular elements.
Serum  and plasma samples for non -pharmacogenetic bio marker research will be co llected at the 
times specified in the Schedule of Act ivities (Section 1.3)where local regulat ions allow.
Samples will  be used for research on the drug target, dis ease process, variable response to 
LY3209590 pathways associated with T1DM , mechanisms o f action of LY3209590 and/or 
research methods or in validating diagnostic tools or assay (s) related to T1DM .
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the invest igator site personnel.  
Samples will  be retained for a m aximum  15 years after the l ast pati ent vi sit for the study , or f or a 
shorter period if local regulat ions and ethic review boards impose shorter time limits, at a facilit y 
selected by  Lilly.  This retenti on peri od enables use of new techno logies, response to regulatory  
questions, and invest igation of variable response that m ay not be observed unt il later in the 
development of LY3209590 or after LY3209590 become(s) commercially available.
8.9. Immunogenicity Assessments
At the visit s and t imes specified in the Schedu le of Act ivities (Secti on1.3), venous blood
samples will be co llected for analysis to determine antibody production against LY3209590.  
Antibodies may be further characterized for cross -reactive binding to insulin. In vivo laboratory  
indicators for glycemic control ( e.g.,BG,HbA1c , and /ordaily insulin dose ) may be utilized to 
detect a poten tial neutralizing effect of antidrug antibodies ( ADA s)against LY3209590. To 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 58interpret the resul ts of immunogenicit y, a venous blood sample will be collected at the same time 
points to determine the plasma concentrations of LY3209590.  All samples for immunogenicit y 
shoul d be taken predose when applicable and possible .
Treatment -emergent (TE) ADAs are defined in Section 9.4.8 . If the immunogenicit y sample at 
the last scheduled assessment or discont inuat ion visit is TE -ADA pos itive, addit ional samples 
may be taken unt il the signal returns to baseline (i.e. ,no longer TE -ADA posit ive) or for up to 1 
year after last dose.  
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit, or for a shorter 
period if local regulat ions and Ethical Review Boards (ERBs) allow, at a facilit y selected by  the 
sponsor.  The duration allows the sponsor to respond to future regulatory  requests rel ated to 
LY3209590 .  Any samples remaining after 15 years will be destroyed. 
8.10. Health Economic s
No heal th economic outcomes are planned.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 599. Statistical Considerations
9.1. Statistical Hypotheses
The primary  hypothesis is to test whether LY3209590 treatment is non-inferior to insulin 
degludec in HbA1c change from baseline to Week 26 in study  partici pants who are MDI treated 
T1DM , using a non -inferiorit y margin (NIM) of 0.4% .
9.2. Sample Size Determination
Approximately  238 participant s will be rando mized to study treatm ent (LY 3209590 A lgorithm 1 , 
and insulin degludec) such that approximately 11 9participants will be rando mized to each 
treatm ent. Assuming a 20% dropout rate, approximately 190 participants will complete the 
study  (approximately 9 5 participant s per treatment group) .  
The190 participants who complete the treatment will provide at least80% statist ical power to 
demonstrate the noninferiorit y in the change in HbA1c fro m baseline to 26 weeks for 
LY3209590 Algori thm 
1versus insulin degludec ,based on the fo llowing assumpt ions:
True m ean difference = 0%
SD of 1. 1%
NIM of 0.4%
Using 2-sided alpha level o f 0.1
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 609.3. Populations for Analyses
The following popul ations are defined:
Population Description
Entered /Enrolled
Popul ationAll participants who sign the ICF
Randomized Popul ation All participants assigned to treatment, regardless of wh ether they  
take any  doses of study  treatm ent, or if they took the correct 
treatm ent.  The participants previously randomized to Algorithm 
2 will be pooled wi th the parti cipants randomized to Algorithm 1
and all of these parti cipants will  be analyzed asone treatment 
group of LY3209590.
Efficacy Population Parti cipants in randomizat ion populat ionexcluding the 
participants previously rando mized to Algorithm 2. 
SafetyPopul ation All participants rando mly assigned to study  treatment and who 
take at least 1 dose of study  treatm ent. The participants 
previously rando mized to Algorithm 2 will be pooled with the 
participants randomized to Algorithm 1 and all o f these 
participants will be analyzed as one treatment group of 
LY3209590 .
Pharmacokinet ic 
Popul ationAll rando mized participants who received at least 1 dose of 
LY3209590 and have at least 1 evaluable PK sample.
Abbreviations:   ICF = informed consent form; PK = pharmacokinetics.
9.4. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y ofsponsor or its designee .
All tests of treatment effects will be conducted at a 2 -sided al pha level of 0. 1, unl ess otherwise 
stated, and all confidence intervals (CIs) will be given at a 2 -sided 9 0% level.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making t
he change, will be described 
in the statist ical analysis plan ( SAP)and the clinical study  report.  Addi tional expl oratory  
analyses o f the data will be conducted as deemed appropriate.
The SAP will include a more technical and detailed descript ion of the s tatistical analyses 
described in this sect ion. This sect ion is a summary o f the planned statist ical analyses of the 
most im portant endpoints including primary and key  secondary  endpoints.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 619.4.1. General Considerations
Unless otherwise stated, the efficacy  analys es will  be conducted on efficacy analyses set (EAS) 
based on the Efficacy Popul ation using the data up to the study  treatm ent discont inuat ion 
(defined as the observed data with co llection date before or at the last dose date +10 days).
Sensit ivity analyses for selected efficacy measures may be conducted on the Rando mized 
Popul ation using the data up to the study  treatm ent discont inuat ion.
Unless otherwise stated, thesafet y analyses except for hy poglycemia will be conducted on the 
safet y analyses set based on the Safet y Popul ation using all data collected during the study  
including treatment and fo llow-up peri od regardl ess of the treatment disposit ion status. The 
details for analyses ofhypoglycemia will be documented in the SAP.
Unless otherwise specified, t hebaseline value used for the analyses will be the last nonmissing 
value obtained for each pa rticipant prior to or onthe date of first study  IP dose (or randomizat ion
visit date if first dose date is missing) . The baseline li ver enzyme lab measures will be the 
average o f allassessments prior to and at randomization visit .
9.4.2. Treatment Group Comparability
9.4.2.1. Patient Disposition
All randomized pa rticipant swho discontinue the study /treatm entwill be identified, and a reason 
for thei r discont inuat ion will be given.  The reasons for study/treatment discont inuation swill be 
listed and will be summarized by treatment. The discontinuat ion due to an AE will be 
summarized by  AEand treatm ent. The percentage of participant sdiscont inuing from each 
treatm ent will be compared using the Fisher’s exact test.
Reasons for discont inuat ion prior to randomization will also be summarized.
9.4.2.2. Patient Characteristics
Dem ographic and baseline characterist ics will be summarized by treatment group for 
Randomized Populat ionandEfficacy Populati on.  Categori cal variables will be summarized by  
frequencies and percentages , and comparisons between treatment groups will be assessed using a 
Pearson Chi -Square test.  Conti nuous variables will be summarized by  mean and standard 
deviat ion, and compar isons between the treatment groups will be performed using a 1
-way 
analysis of variance with treatment as the fixed effect.
9.4.2.3. Concomitant Therapy
Summary  of concomitant therapies will be provi ded by  treatm ent group for all rando mized 
participant s.
9.4.2.4. Treatment Compliance
Treatment compliance will be assessed using the EAS and summarized by treatment . The 
incidence of missed dose and the percentage of missed dose will be evaluated.
Adherence to the dosing algorithm will be assessed based on the number and percentage of 
investigator prescribed doses that did not fo llow the inv estigator -calculated al gorithm dose and 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 62the number and percentage of pa rticipant actual administration dose that did not fo llow the 
investigator prescribed dose .
9.4.3. Primary endpoint(s)
The primary  object ive is to compare the HbA1c change fro m baseline to Week 26between 
LY3209590 treatm entand insulin d egludec .  It i s intended to estimate the treatment differences 
in the change in HbA1c from baseline to 26 weeks if participants adhered to the treatment 
without intercurrent events (stop of the study  medicati on).  It is a ty pe of hypothetical est imand 
based on International Council for Harmonisation (ICH) E9(R1). Only d ata before the 
occurrence of the intercurrent events (stop of the study  medicat ion) will be included in the 
analysis and the result ing missing values will be imputed implicit ly in the mixed -effect m odel for 
repeated m easurem ents ( MMRM ) analysis . The MMRM model will include treatment, coun try, 
visit, and treatment by  visit interacti on as fixed factors and the baseline of the dependent variable 
as a continuous covariate. 
As a sensit ivity analysis, the treatm ent differences in HbA1c change from baseline to Week 26,
only ifpatients coul d com plete the treatm ent, will also be estimated. More details will be 
specified in the SAP. 
9.4.4. Secondary endpoint(s)
The following secondary  efficacy outcom es will be analyzed :
HbA1c change fro m baseline to 12 weeks
FGand c hange from baseline at 12 and 26weeks
Bolus insulin dose change fro m baseline to 12 and 26 weeks
9.4.5. Tertiary/exploratory endpoint(s)
Refer to the SAP for analyses related to tertiary /expl oratory  endpoints.
9.4.6.
Safety Analyse (s)
Unless otherwise stated, all safet y analyses will be based on the safet y analysis set .  Safet y 
measures include treatm ent exposure, AEs, vital signs, hypoglycemic episodes, laboratory  
measurements, ECG and immunogenicit y.
9.4.6.1. Adverse Events
AEs will be summarized as TEAEs (defined as events that are newly reported after 
rando mizat ion or reported to worsen in severit y from baseline).  The incidence of participants
with at least 1 TEAE and the incidence of TEAEs by  preferred term  and system org an class will 
be presented by  treatm ent group.  The frequency  and percentage of participant s for each 
preferred team will be presented.  The incidence of pa rticipant swith at least 1 TEAE assessed as 
possibly  related to the invest igational drug will be sum marized by  treatm ent group, in addit ion to 
the incidence of these possibly  related TEAEs by  preferred term .  In addi tion, a summary  of 
TEAEs by  severi ty will be presented descript ively by treatment group.
Reported and adjudicated CVswill be listed by participant , and if there are a sufficient number 
of cases they  may be summarized by  treatm ent group.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 63All SAEs will be listed by  participant .  If a sufficient number of SAEs are reported, incidence 
summaries similar to incidence of TEAEs will be included.
Discontinuati ons due to AE will be summarized by treatment group and preferred term .
9.4.6.2. Vital Signs
Descript ive statistics for the actual measurements and changes from baseline will be presented 
by treatment group and visit.  Corresponding figures may be presente d.Vital signs will  be 
analyzed using a MMRM model
.
9.4.6.3. Hypoglycemia Episodes
The incidence and rate per y ear of hypoglycemi awill be presented for the periods between 
0-12 weeks , 12 -26weeks , 0-26 weeks ,and the follow-up period and analyzed according to the 
hypoglycemia definit ions described in the American Diabetes Associat ion classificat ion system
(ADA 2019 ).The analyses for hy poglycemia will be performed on E fficacy Population and 
additionally  the severe (l evel 3) hypoglyce mia analysis will also be performed for the Safety 
Population.
9.4.6.4. Laboratory Measures
Summary  statistics will be provided for laboratory  measures by  treatm ent group and by visit. An 
additional listing will be presented for all laboratory measurements that ar e outside the normal 
range.
Descript ive statistics for the laboratory analyses will be presented by treatment group and visit.
Laboratory  analyses wi th categori cal responses will be summarized by  visit and treatment group 
using frequency  and percentage.
The maximum/minimum post- baseline observation (as applicable for a lab) will be co mpared to 
the baseline observat ion by examining the proportion of participant s whose test values are within 
and outsi de the reference ranges.
9.4.6.5. Electrocardiograms
ECG is mainly for participant safet y monitoring. Exploratory  analysis may  be conducted as 
necessary .
9.4.6.6. Adverse Events of Special Interest
Hypoglycemia and allergic/hypersensit ivity react ions are defined as AESIs (Secti on 8.3.7 ).
Descript ive statistics for the AESIs will be presented by treatment group.  
9.4.7. Pharmacokinetic/Pharmacodynamic Analyses
LY3209590 concentration data will be analyzed using a populat ion PK app roach via nonlinear 
mixed -effects m odeling wi th the NONMEM software. The relationships between LY3209590
dose and/or concentration and efficacy, tolerabilit y, and safet y as well as bio marker endpoints 
will be characterized if exploratory  analyses of the P D data warrant further PK/PD analyses upon 
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 6 4 re vie w. S uc h a nal yses ma y i ncl u de, b ut are n ot necessaril y li mite d t o, gl uc ose, H b A 1c, Q Tc, 
h y p o gl yce mia, a n d vital si g ns. 
I n a d dit i o n, if p o p ulat i o n P K a n d P K/ P D m o dels ca n be esta blis he d ,t h e i m pact of a d dit i o nal  
parti ci pa nt fact ors ,s uc h as a ge, wei g ht, ge n der a n d re nal f u nct i o n o n P K a n d/ or P D para meters, 
ma y be e xa mi ne d. S h o ul d a nt i dr u g a nti b o d y be detecte d fr o m i m m u n o ge nicit y testi n g, its 
i m pact o n L Y 3 2 0 9 5 9 0 P K or a n y  r el e va nt P D para meters will als o be e xa mi ne d. 
9. 4. 8. E v al u ati o n of I m m u n o ge nicit y 
T he fre q ue nc y a n d perce nta ge of pa rti ci pa nt s wi t h  pree xist i n g A D A a n d wit h T E -A D A t o 
L Y 3 2 0 9 5 9 0 ma y be ta b ulate d. Treat me nt -e mer ge nt A D As are defi ne d as t h ose wit h a titer 
2- f o l d ( 1 dil uti o n) greater t ha n t he mi ni m u m re q ui re d dil ut i o n if n o A D As were detecte d at 
baseli ne (treat me nt -i n d uce d A D A) or t h ose wit h a 4 -f o l d ( 2 dil uti o ns) i ncrease i n titer c o m pare d 
t o baseli ne if A D As were detecte d at baseli ne (treat me nt -b o oste d A D A). 
T he fre q ue nc y of cr oss -reacti ve bi n di n g t o i ns uli n ma y als o be ta b ulate d i n T E A D A + s u bjects, 
w he n a vaila ble. 
T he rel at i o ns hi p bet wee n t he prese nce of a nt i b o dies a n d t he P K para meters a n d P D res p o nse 
i ncl u di n g safet y a n d efficac y  t o L Y 3 2 0 9 5 9 0ma y be assesse d. 
9. 4. 9. Ot her A n al yses 
Detaile d a nal ysis pla n f o r C G M will be d oc u me nte d i n t he S A P. 
9. 5. I nteri m A n al yses 
9. 6. D at a M o nit ori n g C o m mittee ( D M C) 
N o D M C i s pla n ne d f or t his st u d y .C CI 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 6510. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regu latory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
oConsensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Or ganizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
oApplicable ICH GCP Guidelines
oApplicable laws and regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., adverti sements) 
must be submitted to an IRB/IEC by  the invest igator and reviewed and approved by the IRB/IEC
before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to elim inate an immediate 
hazard to study  parti cipants.
Under emergency  circumstances, deviations from this protocol to protect the rights, safety , or 
well-
being of participants are allowed without prior approval of Lilly and the IRB/IEC. The site 
shall document and report these emergent deviat ions to Lilly  and the IRB/IEC wi thin 5 working 
days after the emergency occurred.
Deviat ion(s) fro m this protocol , signed 1572, applicable regulat ions, and any condit ions of 
approval  imposed by an IRB /IEC or applicable regulators shall be documented (including date of 
and reason for deviation).  Site personnel must ident ify and report deviations to the sponsor 
within 5 working days.
If appropriate, actions to secure compliance may be taken by  Lilly.  These act ions may include 
removal or discont inuat ion ofstudy  intervent ion materi als, rem oval/disposal o f devices fro m the 
investigator, or terminat ion of an invest igator’s participat ion in the study .
The invest igator will be responsible for the fo llowing:
oProvi ding wri tten summaries of the status of the study  to the IRB/IEC a nnually or 
more frequent ly in accordance wit h the requirements, policies, and procedures 
established by  the IRB/IEC
oNotifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures
oProvi ding oversight of the conduct of t he study at the site and adherence to 
requi rements of 21 CFR, ICH guidelines, the IRB/IEC, European regulat ion 536/2014 
for clinical studi es (if applicable), and all other applicable local regulat ions
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 6610.1.2. Financial Disclosure
Invest igators and sub -invest igator s will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Invest igators are 
responsible for providing informat ion on financial interests during the course of the study  and for 
1 year after complet ion of the study .
10.1.3. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study , including the ri sks 
and benefits, to the parti cipant or his/her legally  authori zed representati ve and answer all
questions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary.Participants or thei r legally 
authori zed representative will be required to sign a statement of informed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portabilit y and 
Accountabilit y Act (HIPAA) requirements, where applicable, and the I RB/IEC or study cente r.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authori zed person obtaining the informed consent must also sign th e ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  authori zed 
representati veand is kept on file.
Parti cipants who are rescreened are required to sign a new ICF.
10.1.4. Data Protection
Parti cipants will be assigned a unique identifier by the sponsor. Any participant records ,datasets
or tissue samples that are transferred to the sponsor will contain the ide ntifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used by  the 
sponsor in accordance wit h local data pr otecti on law. The l evel of discl osure must al so be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent
The parti cipant must be inform ed that hi s/her m edical  records m ay be exami ned by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
10.1.5. Dissemination of Clinical Study Data
Reports
The sponsor will disclose a summ ary of study  information, including tabular study results, on 
publicly available websites where required by  local law or regul ation. 
Data
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 67The sponsor provides access to all individual participant data collected during the trial, after 
anonymizat ion, wi th the excepti on of  PKor genetic data.   Data are available to request 6 months 
after the indicat ion studied has been approved in the United States ( US)and European Unio n 
(EU)and after primary publicat ion acceptance, whichever is later.  No expirat ion date of data 
requests is current ly set once data are made available.  
Access i s provi ded af ter a proposal  has been approved by an independent review committee 
ident ified for this purpose and after receipt of a signed data sharing agreement. Data and 
docum ents, including the study  protocol , statistical analysis plan, clinical study  report, bl ank or 
annotated case report forms, will be provided in a secure data sharing environment for up to 2 
years per proposal.  
For details on submitting a request, see the instructio ns provided at 
www.clinicalstudy datarequest.com .  
10.1.6. Data Quality Assurance
All participant data relat ing to the study  will be reco rded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e .g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electronically 
signing the CR F.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct a ccess to source data documents.
Moni toring details describing strategy  (e.
g., risk -based init iatives in operations and qualit y such 
as Risk Management and Mit igation Strategies and Analyt ical Risk-Based Monitoring), methods, 
responsibilit ies and requirements , including handling of nonco mpliance issues and monitoring 
techniques (central, remote, or on -site monitoring) are provided in the contracts.
The sponsor or designee is responsible for the data management of this study  includin g qualit y 
checking o f the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (e
.g., Contract 
Research Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  parti cipants are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, a nd all applicable regu latory requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for 15years after study completion unless local regulat ions or 
institutional policies req uire a l onger retenti on period. No records may be destroy ed during the 
retenti on peri od wi thout the wri tten approval  of the sponsor. No records may be transferred to 
another location or party  without wri tten notificat
ion to the sponsor .
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 68In addit ion, the sponsor or its representatives will periodically  check a sample of the parti cipant 
data recorded against source documents at the study site.  The study  may be audi ted by the 
sponsor or its representatives, and/or regulatory  agencies at any  time.  Invest igators will  be given 
notice before an audit occurs.  
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor. 
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any da ta to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF .
Addit ionally , eCOA data ( participant -focused outcom e instrument ) will be direct ly recorded by  
the participant , caregiver , and/or invest igator site personnel, into an instrument ( e.g., handheld
smart phone or tablet).   The eCOA data will serve as the source documentation and the 
investigator does not maintain a separate, written or electronic record of these data.  
The invest igator will have continuous access to the data during the study and unt il 
decommissio ning of the data capture sy stem .  Pri or to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as labora tory test data, will be stored electronically  in 
the central  vendor’s database system and reports/electronic transfers will be provided to the 
investigator for review and retention.  Data will subsequent ly be transferred fro m the central  
vendor to the sponsordata warehouse.
Data from co mplaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management sy stem .
Study Procedures
Electronic Clinical Outcomes Assessment
The use of eCOA eDiaries should also allow more complete and accurate capturing of 
hypoglycemic events, correction boluses and dosing, as well as more frequent and timely 
interact ions between invest igator and patients as the intensit y of their individual diabetes 
management increases.   
Physicians and designated clinical staff will have access via the eCOA portal (secured web -based 
site) to BG readings, hypoglycemic events, correctio n boluses and dosing information for each 
patient once transferred.  It is recommended that investigators review pat ient data via the eCOA 
portal  at least once weekly for clinical decisio n making and safety  monitoring. More frequent 
reviews may be necessary  for individual  patient management.
An instructi on m anual will be provided to patients and invest igative sites. Addit ional instructi on 
and training will be provided to the invest igative sites regarding data collect ion, review, 
retenti on, and archival processes. In the event of eCOA eDiary malfunct ion or l oss, the pati ent 
will be instructed to immediately contact th e investigat ive site for instructions regarding 
replacement of the equipment.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 69Correction Boluses
Patients will  be instructed to enter all non -meal-related correcti on bo lus doses (those not 
associ ated wi th a meal or combined with a meal bolus) into the eCOA diary .
Hypoglycemia
Hypoglycemic events will be entered by  the pat ient throughout the clinical study  in eCOA alo ng 
with date and time of the BG level if measured and hy poglycemia treatm ent and outcom e data. 
Self-Monitoring Blood Glucose
Patients will  beinstructed to perform Daily Fast ing BG values are expected as well as 6 -point 
SMBG according to the Schedule of Activities(Secti on 1.3).  
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcri bed fro m source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on the 
study . Also, current medical records must b e available.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any reason at the sole discret ion of the sponsor. Study  sites will be cl osed upon study  
completion.A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include b ut are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator
Discontinuat ion of further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The Invest igator shall prompt ly inform  the participant and should 
assure appropriate therapy  and/or foll ow-up
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 7010.1.9. Publication Policy
In accordance with the sponsor’s publication po licy the results of this study will be submitted for 
publicat ion by a peer -reviewed journal.
10.1.10. Investigator Information
Principal investigators who are a diabetologist, internal medicine specialist, or primary care 
physician wit h experience in the care of ty pe 1diabetes pati ents using MDI and CGM will 
participate as invest igators in this clinical trial.
10.1.11. Long -Term Sample Retention
Sample retenti on enables u se of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of  
LY3209590 or after LY3209590 beco mescommer cially available.   
The fo llowing tabl e lists the m aximu m retention period for sample ty pes.  The retention period 
begins after the last participant visit for the study . Any samples remaining after the specified 
retenti on peri odwill be destroy ed.
Sample Type CustodianRetention Period After 
Last Patient Visit*
Long -term storage samples Sponsor or Designee 15 years
Biomarkers Sponsor or Designee 15 years
PK Sponsor or Designee 1 year
Genetics Sponsor or Designee 15 years
PD Sponsor or Designee 2 years
Immunogenicity Sponsor or Designee 15 years
Abbreviations:  PD = pharmacodynamics; PK = pharmacokinetics.
*Retention periods may differ locally.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 7110.2. Appendix 2: Clinical Laboratory Tests
Addit ional tests may be performed at any  time during the study  as determined necessary  by the 
investigator or required by local regulat ions.
Invest igators must document their review of each laboratory  safety  report.
Refer to Section 10.9 for recommended labora tory testing for hypersensit ivity events.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 72Clinical Laboratory Tests a
Hematology Clinical Chemistr y
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Chloride
Mean cell volume (MCV) Bicarbonate
Mean cell hemoglobin (MCH) Total bilirubin
Mean cell hemoglobin concentration (MCHC) Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Gamma glutamyltransferase (GGT)
Eosinophils Blood urea nitrogen (BUN)
Basophils Creatinine
Platelets Uric acid
Calcium
Urinalysis Phospho rus
Protein Glucose
Nitrite Total protein
Blood Albumin
Urine leukocyte esterase Creatine kinase (CK)
Cholesterol
Hormones
Pregnancy test serum and urine(females only) bTriglycerides
Pancreatic amylase
Follicle stimulating hormone Lipase
Endocrine Lipid Panel
C-Peptide HDL cholesterol
LDL cholesterol
Hemoglobin A1c
Free Fatty Acid
Hepatitis B
Hepatitis B Core Antibody
Hepatitis B Surface Antigen
Hepatitis B Surface Antibody
Immunogenicit ycDrug concentratio nc
Anti-LY3209590
Calculation
eGFR (Calculated by CKD -EPI equation)LY3209590
Pharmacogenetic samplec
Non-pharmacogenetic samplesc
Serum
EDTA Plasma
Abbreviations:   CKD -EPI = chronic kidney disease epidemiology collaboration;
EDTA =Ethylenediaminetetraacetic acid ;eGFR = estimated glomerular filtration rate; HDL = high density 
lipoprotein; LDL = low density lipoprotein; RBC = red blood cells; WBC = wh ite blood cells.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 73aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted.
bUrinepregnancy test s(analy zed on -site) to be performed at Visit s3 and 801/ED2, and serum pregnancy test 
(analy zed by  central laborato ry) to be performed at Visits 1 for women of childbearing potential .  Additional
pregnancy tests may be performed at the investigator’s discretion during the study .
cResults will not be provided to the investigative sites.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 7410.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any  unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e .g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medical and scient ific judgment of the investigator (i .
e., not related to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/ self-harming 
intent. Such overdoses should be reported regardless of sequelae.
Note:  “Lack of efficacy” or “failure of expected pharmaco logical act ion” per se will 
notbe reported as an AE or SAE. Such instances will be captured in the efficacy 
assessme nts. However, the signs, symptoms, and/or clinical sequelae result ing from 
lack of efficacy  will be reported as AE or SAE if they fulfil the definit ion of an AE or 
SAE.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 75Events NOT Meeting the AE D efinition
Any clinically  significant abnormal laboratory findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure (e .g., endoscopy , appendectomy): the condit ion that 
leads to the procedure is the AE.
Situations in which an untoward m edical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Defini tion of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e .g., hospitalizat ion for signs/symptoms of the disease under study , death due to 
progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer t o an event, which 
hypotheti cally  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal
for observat ion and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Com plicati ons that occur during 
hospi talizati on are AEs. If a co mplication prolongs hospitalization or fulfills any other 
serious cri teria, the event is serious. When in doubt as to whether “hospitalizat ion” 
occurred or was necessary, the AE should be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen 
from baseline is not considere d an AE.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 76d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significanc e such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma (e .g., sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disrupt ion.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately  life-threatening or result in death or hospitali zation but m ay jeopardi ze the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or m alignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsio ns that do not result in hospitalizat ion, or development of drug dependency or 
drug abuse .
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e .g., hospital progress notes, laboratory  reports, and di agnosti cs 
reports) related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records in lieu of co mpletion of the AE/SAE CRF page.
There m ay be instances when copies of medical records for certain c ases are requested 
by sponsor. In this case, all participant ident ifiers, with the exception of the participant 
number, will be redacted on the copies of the medical records before submissio n to 
sponsor .
The invest igator will attempt to establish a diagno sis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE .
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 77Assessment of Intensity
The invest igator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to 1 of the fo llowing categori es:
Mild: An event that is easily tolerated by  the partici pant, causing minimal discomfort 
and not interfering with everyday act ivities.
Moderate: An ev ent that causes sufficient discomfort and interferes wit h norm al 
everyday act ivities.
Severe: An event that prevents normal everyday activit ies. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal rel ationship, rather than a relat ionship cannot be 
ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal re lationship of the event to study intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the Invest igator’s Brochure (IB) and/or Product 
Inform ation, for marketed products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to the sponsor. However, it is very 
important that the invest igator always make an assessment of causalit y for every  event 
before the init ial transmissio n of the SAE data to sponsor .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 78Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested to elucidate 
the nature and/or causalit y of the AE or SAE as fully  as possible. This m ay include 
additional laboratory  tests or invest igations, histopathological examinat ions, or 
consultation wit h other health care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up 
period,the invest igator will provide sponsor with a copy of any post -mortem findi ngs 
including histopathology .
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will submit any updated SAE data to sponsor within 24 hours of 
recei pt of the inform ation.
10.3.4. Reporting of SAEs
SAE Reporting to Sponsor via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE to sponsor will be the electronic data 
collect ion tool .
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exist ing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this informatio n on a paper SAE form (see ne xt 
section) or to the Lilly Medical by telephone.
SAE Reporting to Sponsor or designee via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the Lilly Medical .
In rare circumstances and in the absence of facsimile equipment, notificat ion by 
telephone is acceptable wit h a copy  of the SAE data collect ion tool  sent by  overnight 
mail or courier service.
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 7910.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and until beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, additional eval uation shoul d be considered.
Women in the fo llowing categori es are not considered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above, (e .g., mullerian agenesis, androgen insensit ivity), invest igator discret ion shoul d be 
applied to determining study  entry .
Note: Documentation can co me from the site personnel’s :review o f the parti cipant’s 
medical records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as, women with:
i.A wo man at l east 40 years of age with an intact uterus, not on hormone therapy , 
who has cessat ion of menses for at least 1 year without an alternat ive medical 
cause, AND a follicle-stimulat ing hormone >40 mIU/mL; or
ii.A wo man 55 or older not on hormone therapy , who has had at l east 12 m onths of 
spontaneous amenorrhea; or
iii.A wo man at l east 55 years of age with a diagnosis of menopause pri or to starting 
horm one repl acement therapy .
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only  to 
male participants who receive study  intervent ion
.
After obtaining the necessary  signed informed consent from the pregnant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24hours of learning of the partner’s pregnancy. The female partner will also be 
followed to determine the outcome of the pregnancy . Informati on on the status of the mother 
and child will be forwarded to the sponsor. Generally, the fo llow-up will be no longer than 6 to 
8weeks following the est imated delivery date. Any terminat ion of the pregnancy will be 
reported regardless of fetal status (presence or absence o f anomalies) or indicat ion for the 
procedure. 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 80Female Participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who becomes 
pregnant while part icipating in this study . The init ial information will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning o f a participant's 
pregnancy. 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generall y, follow-up will not be required for longer than 6 to 8 weeks 
beyo nd the est imated delivery date. Any termination of pregnancy will be reported, regardless o f 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
While pregnanc y itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurri ng at 
>22weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any post -study pregnancy related SAE considered reasonably related to the study intervention 
by the investigator will be reported to the sponsor as described in Sect ion8.3.4 . While the 
investigator is not obligated to actively seek this informat ion in former study  parti cipants, he or 
she m ay learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will discont inue 
study  interventi on or be wi thdrawn from  the study .
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 8110.5. Appendix 5:Liver Safety: Suggested Actions and Follow -up 
Assessments
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalised 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by sponsor -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 8210.6. Appendix 6: New York Heart Association Cardiac Disease 
Classification
Functional Capacity
Class I
Patients with cardi ac disease but without resulting limitation of physical activit y.  Ord inary 
physical act ivity does not cause undue fat igue, palpitation, dy spnea, or anginal pain.
Class II
Patients with cardi ac disease result ing in slight limitat ion of physical act ivity.  They  are 
comfortable at rest.  Ordinary  physical activi ty resul ts in f atigue, palpitat ion, dy spnea, or anginal 
pain.
Class III
Patients with cardi ac disease result ing in marked limitat ion of physical act ivity.  They  are 
comfortable at rest.  Less than ordinary  activity causes fat igue, palpitat ion, dyspnea, or anginal 
pain.
Class IV
Patients with cardi ac disease result ing in inabilit y to carry  on any physical act ivity without 
discomfort.  Symptom s of heart failure or the anginal syndrome may be present even at rest.  If 
any physical act ivity is undertaken, disco mfort increases .
1994 Revisio ns to Cl assificati on of  Funct ional Capaci ty and Objective Assessment of Patients 
with Diseases of the Heart
Reprinted with permission
www.am ericanheart.org
© 2011, American Heart Associat ion, Inc.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 8310.7. Appendix 7: Genetics
Use/Analysis of DNA
Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, and 
severit y and progressi on of  disease. Variable response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion,metabo lism, and excreti on; 
mechanism o f action of  the drug; di sease et iology; and/or m olecular subt ype of the disease being 
treated. Therefore, where local regulations and IRB/IEC allow, a blood sample will be co llected 
for DNA analysis fro m consenting p articipants.
DNA samples will be used for research related to study  intervent ion or T1DM and related 
diseases.  They  may also be used to develop tests/assays including diagnost ic tests related to 
study  interventi on and/or intervent ions of this drug class a nd T1DM .  Genet ic research may 
consist of the analysis of one or more candidate genes or the analysis o f genet ic markers 
throughout the geno me or analysis o f the ent ire geno me (as appropriate).
The samples may  be analyzed as part of a mult i-study  assessmen t of genetic factors involved in 
the response to study  intervent ion or study  intervent ions of this class to understand study  disease 
or rel ated condi tions.
The results of genet ic analyses may be reported in the clinical study  report (CSR) or in a separate 
study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be retained as described in Section10.1.11 .  
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 8410.8. Appendix 8: Dosing Guidance for LY3209590 and Insulin Degludec
10.8.1. LY32 09590 Algorithm 1 (paper algorithm) 
In Study  BDCP ,
apaper dosing Algorithm 1 will be used by invest igators for init iating and 
adjusting LY3209590 toachieve the target FG ≤100 mg/dL (<5.6 mmo l/L). 
In situations where study  partici pant safet y is a concern ,investigators may make adjust ments to 
the dose of LY3209590 recommended by  the dose -adjustment algorithm in Table 2; however, 
clinical rationale must be documented in the eCRF and Lilly Medical must be informed about 
this deviat ion and associated medical rationale .If the invest igator has safet y concerns about the 
algorithm, the invest igator is to contact the Lilly CRP.
At the time of site visit, the investigator will assess the study  parti cipant’s glycemic control for 
the previous week and, if necessary, inform the study  parti cipant about any  needed dos e 
adjustm ent. The dose will be based on the study  parti cipant’s FGvalue obtained from the CGM 
system  prior to the m orning meal and hypoglycemia docum ented in the electronic diary  in the 
previous week. Adherence to the dosing algorithm provided for this study  is requi red from 
Visit3 (randomizat ion) up to Week 25 and will be mo nitored peri odically  by the study  team .  
General Algorithm Considerations:
The treat -to-target FG in the algorithm is ≤100 m g/dL (<5.6 mmo l/L).  LY3209590 dose 
adjustm ents will be determined based on the median of the FG (determined fro m SMBG
obtained fro m the CGM system, referred to as SMBG below) of at least 3 day s (up to 7 
days) obtained in the previous week leading up to the visit.
The LY3209590 dose may  not be increased if any  SMBG reading was documented at 
≤70 m g/dL (<3.9 mmo l/L) at any  time in the prec eding week. Dose decreases of 0.5 mg 
adjustm ent m ay be permi tted if mul tiple episodes of hypoglycemia wit h SMBG ≤70 
mg/dL (<3.9 mmo l/L) were re corded, or dose decrease of 1 mg if severe hypoglycemia 
(requiring assistance) occurred, or if any  SMBG was docum ented at ≤54 mg/dL (≤3.0 
mmo l/L) in the preceding week.
In dosing calculat ions where rounding is required, round to the nearest 0.25 mg.
The st arting LY3209590 dose is determined based on both the prior basal insulin dose and 
baseline fasting glucose.  Participants may enter the study using insulin glargine, detemir, or 
degludec.  Consistent with product labeling these insulins may be transit ioned on a uni t-for-unit 
basis and for the purposes of this protocol are considered equivalent.  Because of the long half -
life o f LY3209590, the change in fast ing glucose response may take several weeks to reach a 
steady -state response; therefore, to minimize the time needed to achieve the desired target 
glycemic response, a loading dose strategy  will be used for the first dose only .  Directions are 
provi ded below to convert current basal insulin dose (in Unit s, U) to the dose of LY3209590 (in 
mg) for determina tion of  the starting weekly dose and for dose adjust ments at subsequent Visits.  
Examples for Visits 3 -6 are provi ded in italic text.
Visit 3 (Randomization Visit): 
1.Obtain the prior daily  basal insulin dose of insulin glargine, detemir, or degludec asses sed 
during the lead- in period .  Cal culate the “basal insulin equivalent dose” of LY3209590 
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 8 5 (i n m g) b y di vi di n g t he t otal  dail y  d ose of basal i ns uli n ( U) b y t he c o n versi o n fact or of 
7U/ m g.  
F or ex a m ple, if a p artici p a nt uses 3 5 U of de gl u dec e ac h d ay, 3 5 U÷ 7 U/ m g = 5 
m g of L Y 3 2 0 9 5 9 0 .
2. T he d ose of L Y 3 2 0 9 5 9 0 m g is t he n f urt her a dj uste d acc or di n g t o me dia n baseli ne fasti n g 
gl uc ose a n d t he parti ci pa nt ’s c urre nt basal i ns uli n d ose ( U) cate g or y as s h o w n i n Ta ble 1 .
F or a p artici p a nt wi t h a me di a n B G v al ue of 1 5 5 m g/ d L, t he d ose a dj ust me nt f or 
t his p artici p a nt c urre ntly usi n g a 3 5 U d ose of de gl u dec w o ul d be + 1. 5 m g. 
3. T he l oa di n g d ose i s o btai ne d b y m ult i p l yi n g t he starti n g t otal  L Y 3 2 0 9 5 9 0 wee kl y  d ose 
(s u m  of  b asal i ns uli n e q ui vale nt d ose a n d t he d ose a dj ust m e nt f r o m  T a ble 1) 
I n t his ex a m ple, 5 m g + 1. 5 m g = L Y 3 2 0 9 5 9 0 t ot al we ekly d ose of 6. 5 m g f or 
a t ot al first d ose of  .  T his first d ose, i ncl u di n g t he l o a di n g d ose ,is use d 
at Visit 3 o nly .
T a bl e 1. L Y 3 2 0 9 5 9 0 D o s e A dj u st m e nt ( m g) U s i n g t h e M e di a n of B a s eli n e 
F a sti n g Gl u c o s e a n d Pri or B a s al I n s uli n D o s e (I nt er n ati o n al U nit s, U) 
Me di a n B aseli ne 
F asti n g Gl uc ose 
( m g/ d L) Me di a n B aseli ne 
F asti n g Gl uc ose b
( m m ol/ L) L Y 3 2 0 9 5 9 0 D ose A dj ust me nt ( m g) a
B as al I ns uli n D ose 
≤ 1 5 U B as al I ns uli n 
D ose 
1 6 – 3 0 U B as al I ns uli n 
D ose 
> 3 0 U 
< 8 0 <4. 4 -0. 2 5 - 1 -1. 5 
8 0 - 1 0 0 4. 4 – 5. 5 N o c ha n ge N o c ha n ge  N o c ha n ge 
1 0 1 – 1 4 0 5. 6 –7. 7 + 0. 2 5 + 0. 5 + 0. 7 5 
1 4 1 – 1 8 0 7. 8 –1 0. 0 + 0. 5 + 1 + 1. 5 
1 8 1 – 2 2 0 1 0 . 1 – 1 2. 2 + 0. 7 5 + 1. 5 + 2 
> 2 2 0 > 1 2. 2 + 1 + 2 + 3 
aT his d ose a dj ust me nt is a d de d t o t he Basal I ns uli n E q ui vale nt D ose t o o btai n t he t otal wee kl y d ose of 
L Y 3 2 0 9 5 9 0 i n m g.  T he starti n g t otal wee kl y d ose of L Y 3 2 0 9 5 9 0 is i ncrease d t o o btai n 
t he first l oa di n g d ose of L Y 3 2 0 9 5 9 0 necessar y t o re d uce t he ti me t o ac hie ve tar get gl yce mic res p o nse.  
bCo n versi o ns fr o m m g/ d L t o m m ol/ L were r o u n d e d off t o pre ve nt o verla p bet wee n t hres h ol d ra n ges a n d t o 
a d dress t hat t he gl uc ose meter dis pla ys 1 si g nifica nt di git after t he deci mal w h e n re p orti n g m m ol/ L rea di n gs .
Vi sit 4 ( W e e k 1) 
1. O btai n t he starti n g t otal  wee kl y d ose L Y 3 2 0 9 5 9 0 m g deter mi ne d at Visit 3. ( T his is 1/ 3 r d 
t h e d ose a d mi nistere d at Visit 3 .) 
Fr o m t he Visit 3 ex a m ple, t he st arti n g L Y 3 2 0 9 5 9 0 t ot al we ekly d ose w a s6. 5 m g. 
2. Use Ta ble 2 t o deter mi ne t he d ose a dj ust me nt  ne e de d f or Visit 4 after caref ull y 
re vie wi n g parti ci pa nt’s fast i n g gl uc ose ( 3 -7 da ys pri or t o visit) a n d h y p o gl yce mia 
d oc u m e nte d si nce t he last L Y 3 2 0 9 5 9 0 d ose .C CI 
C CI 
C CI 
C CI 
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 8 6 T he p artici p a nt re p orte d n o hy p o glyce mi a si nce t he l ast d ose of L Y 3 2 0 9 5 9 0 a n d 
h a d a me di a n F G of 1 5 0 m g/ d L.  Usi n g t he Week 1 ( Visit 4) c ol u m n, t he 
L Y 3 2 0 9 5 9 0 weekly d ose s h o ul d be i ncre ase d by 1 m g. 
6. 5 m g + 1 m g = 7. 5 m g L Y 3 2 0 9 5 9 0 s h o ul d be a d mi nistere d at Visit 4. 
T a bl e 2. W e e kl y D o s e A dj u st m e nt of L Y 3 2 0 9 5 9 0 Usi n g t h e Pr e vi o u s W e e k’ s 
Do s e ( D) u si n g t h e M e di a n F a sti n g Gl u c o s e a n d H y p o gl y c e mi c 
E pi s o d e s   
Me di a n F asti n g 
gl uc ose 
( m g/ d L) aMe di a n F asti n g 
gl uc ose 
( m m ol/ L) a, e Wee k 1 
( Visit 4) 
( 2 n d d ose) Wee k 2 
( Visit 5) 
( 3 r d d ose) S u bse q ue nt 
Wee k c
< 8 0 m g/ d L or 
ha ve a n y n oct ur nal 
h y p o gl yce mia or 
m ulti ple ( ≥ 3) e pis o des 
of h y p o gl yce mia d< 4. 4 m m ol/ L or 
ha ve a n y  n oct ur nal 
h y p o gl yce mia or 
m ulti ple ( ≥ 3) e pis o des 
of h y p o gl yce mia dDb –1. 5 m g Db–1 m g Dc–0. 5 m g 
8 0 – 1 0 0 m g/ d L 4. 4 –5. 5 Db –1 m g Db–0. 5 m g N o c ha n ge 
1 0 1 – 1 4 0 m g/ d L 5. 6 –7. 7 N o c ha n ge N o c ha n ge Dc+ 0. 2 5 m g 
1 4 1 – 1 8 0 m g/ d L 7. 8 –1 0. 0 Db + 1 m g Db+ 0. 5 m g Dc+ 0. 2 5 m g 
> 1 8 0 m g/ d L >1 0. 0 Db + 2 m g Db+ 1 m g Dc+ 0. 5 m g 
aBase d o n me dia n fasti n g gl uc ose fr o m at least 3 fasti n g gl uc ose rea di n gs fr o m pre vi o us wee k. 
bD f or Wee k 1 ( Visit 4) is   of t he d ose a d mi nistere d at ( Wee k 0, Visit 3).  D f or Wee k 2 ( Visit 5) is t he d ose 
a d mi nistere d at Wee k 1 ( Visit 4).  
cD f or S u bse q ue nt Visits is t he d os e a d mi nistere d o ne wee k pri or t o t he c urre nt visit. 
dT he L Y 3 2 0 9 5 9 0 d ose ma y n ot be i ncrease d if a n y S M B G rea di n g was d oc u me nte d at ≤ 7 0 m g/ d L ( < 3. 9 m m ol/ L) 
at a n y  ti me i n t he prece di n g wee k.  If m ulti ple e pis o des of h y p o gl yce mia wit h S M B G ≤ 7 0 m g/ d L ( < 3. 9 m m ol/ L) 
were rec or de d, f oll o w g ui da nce f or d ose re d ucti o n acc or di n g t o t he a p plica ble Visit n u m ber.  D ose decreases of 1 
m g s h o ul d be ma de w he n se vere h y p o gl yce mia (re q uiri n g assista nce) occ urre d, or if a n y S M B G was d oc u me nte d 
at ≤ 5 4 m g/ d L ( ≤ 3. 0 m m ol/ L) i n t he prece di n g wee k. 
eCo n versi o ns fr o m m g/ d L t o m m ol/ L were r o u n d e d off t o pre ve nt o verla p bet wee n t hres h ol d ra n ges a n d t o 
a d dress t hat t he gl uc ose meter dis pla ys 1 si g nifica nt di git after t he deci mal w h e n re p orti n g m m ol/ L rea di n gs .
Vi sit 5 ( W e e k 2) 
1. C o nfir m t h e d ose of  L Y 3 2 0 9 5 9 0 m g a d mi nistere d at Vi si t 4. 
Fr o m t he Visit 4 ex a m pl e,t he L Y 3 2 0 9 5 9 0 weekly d ose w a s 7. 5 m g. 
2. Use Ta ble 2 t o deter mi ne t he d ose a dj ust me nt  nee de d f or Visit 5af ter caref ull y 
re vie wi n g partici pa nt ’s fast i n g gl uc ose ( 3 -7 da ys pri o r t o visit) a n d h y p o gl yce mia 
d oc u m e nte d si nce t he last L Y 3 2 0 9 5 9 0 d ose .C CI 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 87The participant reported no hypoglycemia since the last dose of LY3209590 and 
had a median FGof 153 mg/dL.  Using the Week 2 (Visit 5) column, the 
LY3209590 weekly dose should be increased by 0.5 mg.
7.5 mg + 0.5 mg = 8.0 mg LY3209590 should be administered at Visit 5. 
Visit 6 (Week 3)
1.Confirm the dose of LY3209590 administered at Visit 5 (Week 2).
From the Visit 5 example , the LY3209590 weekly dose was8.0 mg.
2.Use Table 2 to determine the dose adjust ment needed for Visit 6after carefully 
reviewing participant ’sfasting glucose (3 -7 days prior to visit) and hypoglycemia 
docum ented since the las t LY3209590 dose .
The participant reported one episode of nocturnal hypoglycemia since the last 
dose of LY3209590 and had a median FGof 133 mg/dL.  Using the Subsequent 
Week column in Table 2 , and because of the case of nocturnal hypoglycemia, 
LY3209590 dose should be reduced by 0.5 mg .
8.0 –0.5 = 7.5 mg of LY3209590 should be administered at Visit 6.
Subsequent visit s are managed using the same approach as for Visit 6 (Week 3), always 
confirming the LY3209590 dose administered at the prior visit, the median fast ing glucose 
during the week prior to the visits, and hypoglycemia status since the last dose of study  drug.
10.8.2. Insulin Degludec
Adosing algori thm (adapted from  Riddle et al . 2003) will be used b y invest igators for init iating 
and adjust ing insulin degludec to target an FG ≤100 mg/dL (<5.6 mmo l/L) for patients to achieve
glycemic goal. 
In situations where patient safet y is a concern or where dose adjust ments have not had the 
desired therapeut ic effect, investigators may make increased or decreased adjustments to the 
dose of insulin degludec recommended by the dose -adjustment algorithmandhave to document 
the clinical rat ionale for the deviat ionas well as inform Lilly  medical  per email.
At the time of site visit or telephone visit, the investigator will assess the patient’s glycemic 
control  for the previ ous week and, if necessary , inform  the pati ent about any  needed dose 
adjustm ent.  The dose will be based on the patient’s BGvalue.  Adhe rence to the dosing 
algorithm provi ded f or thi s study  is mandatory  from Visi t 3 (randomizat ion) up to Visit 20 
(Week 26), inclusive .  Dose increases may be made at weekly intervals and no sooner than 5 
days fo llowing the last dose increase.  In some cases, patient visi ts coul d occur sooner than 5 
days apart due to the allowable visit window; however, there should be no dose increase if at 
least 5 days have not elapsed since the previous dose increase.  In contrast, the insulin degludec 
dose m ay be reduced a t any  time on the j udgment of the invest igator.  Any deviat ions from this 
guidance must be supported by  clinical  evidence and after consul tation wi thLilly  Medical.  
Insulin dose algorithms have been reviewed by Strange (2007).  The insulin degludec dose 
increase algorithm is adapted from Riddle et al. 2003 and will be determined based on the 
definit ion of what is term ed the “Algori thm FG.”  The Algori thm FG is the m edian of the FG 
(determined from SMBG) of Days 5, 6, and 7 since the last insulin dose increment.  If the 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 88interval  since the l ast dose adj ustment has been lo nger than 7 days, the dose increase is 
determined by the median of the FG of the last 3 days.  If the patient only measured their FG on 
2 of the last 3 day s, then the l esser of  those 2 FG va lues should be used as the Algorithm FG.  If 
only 1 FG m easurement is available for the last 3 days, then the invest igator should use his/her 
discreti on in determining whether there should be a dose adjust ment based on that single FG 
value.
As it is desi red to achieve glycemic goals in as many  patients as possible, contingencies are 
provi ded to accommodate prespecified protocol visits and to increase the dose of insulin 
degludec in a timely  manner.  Therefore, if the last dose increment was 5 days previous, then the 
dose increment is determined by  the Algori thm FG, whi ch is the l esser of the 2 FG values from 
Day 4 and Day 5.  If the dose increment was 6 days previous, then the Algorithm FG is the lesser 
of the 2 FG values fro m Day 5 and Day  6.  In both of th ese cases, if only  1 of the 2 FG val ues is 
available, then the invest igator should use his/her discretion in determining whether there should 
be a dose adjust ment based on that single FG value.
The dose increase algorithm is defined as fo llows:
If the Algo rithm FG is 101 to 120 m g/dL (5.6 to 6.7 mmo l/L), increase the dose by  2 U
If the Algorithm FG is 121 to 140 mg/dL (6.8 to 7.8 mmo l/L), increase the dose by  4 U 
If the Algorithm FG is 141 to 180 mg/dL (7.9 to 10.0 mmo l/L), increase the dose by 6 U 
If the Algorithm FG is 180 mg/dL (10.0 mmo l/L), increase the dose by  8U 
The treat -to-target FG i s ≤100 mg/dL (<5.6 mmo l/L).  The insulin degludec dose will not be 
increased if any SMBG was documented at ≤70 mg/dL (<3.9 mmo l/L) at any  time in the 
precedi ng week.  Dose decreases of 2 to 4 U per adjust ment may be permi tted if mul tiple 
episodes of hypoglycemia with SMBG ≤70 m g/dL (<3.9 mmo l/L) were recorded, if severe 
hypoglycemia (requiring assistance) occurred, or if any  SMBG was docum ented at ≤54 mg/dL 
(≤3.0 mmo l/L) in the preceding week.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 8910.9. Appendix 9:  Recommended Laboratory Testing for Hypersensitivity 
Events
Guidance for l aboratory  assessments for hy persensi tivity events :
Laboratory  assessments should be performed if the participant experiences generali zed urti caria 
or if anaphylaxis is suspected .
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; however, samples may be obtained as late as 12 hours after the event as analytes 
can remain altered for an extende d peri od of  time.  Record the time at which the sample 
was collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit or after 4 weeks, 
whichever i s later.
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 9 0 T a bl e 3. Cli ni c al L a b T e st s f or H y p er s e n siti vit y E v e nt s C CI 
C O N FI D E N TI A L I 8 H- M C -B D C P ( d) 
L Y 3 2 0 9 5 9 0 9 1 1 0. 1 0. A p pe n di x 1 0 :  C h a n ges t o St u d y Pr oce d ures d ue t o t he C O VI D - 1 9 
P a n de mic or N at ur al Dis asters 
Re m ote Visits d uri n g t he St u d y 
If C O VI D 1 9 -or nat ural disaster -relate d tra vel or s helter -i n place restricti o ns are re q ueste d b y  
l o cal/re gi o n al  a ut h ori ti es or f or ot her reas o ns relate d t o t he pa n de mic or nat ural disasters w hic h 
ma ke it i m p ossi ble f or t he partici pa nt t o tra vel t o t he st u d y si t e f or t he m a n dat or y  ti tr ati o n visi ts, 
mit i gat i o ns are re q uire d t o e ns ure safe a n d ti mel y d osi n g of st u d y partici p a n ts. 
T he st u d y  si t e m ust recei ve pri or a p pr o val  b y  Lill y f or eit her site m o bile visits perf or me d b y  
trai ne d site pers o n nel or visits per f o r m e d b y  a q ualifie d h o m e n ursi n g ser vice pr o vi der or ga nize d 
b y t he s p o ns or, wit h vi de o -c o nfere nci n g a bilit y,  t o r e pl ace t he o n -si te visi ts.  
Pr ot oc ol  pr oce d ures, i ncl u di n g bl o o d dra ws, data -d o w nl oa ds, partici pa nt (re -) e d ucati o n, st u d y  
dr u g d ose select io n a n d st u d y  dr u g d osi n g ma y  be perf or m e d at t he parti ci pa nts’ h o me b y 
q ualifie d pers o n nel u nt il tra vel or ot her restrict i o ns are lift e d. 
T he all o we d visit wi n d o ws ca n be e xte n de d base d o n a d vice fr o m Lill y Me dical i n t his 
e xce pti o nal case t o all o w m ore f le xi bilit y i n perf or mi n g t he h o me vis it s. 
E arl y Disc o nti n u ati o n Pr oce d ures: 
If a partici pa nt is q uara nti ne d or c o ntracts C O VI D -1 9 or i s u na ble t o atte n d t he visit f or ot her 
reas o ns d uri n g t he c o urse of t he st u d y  a n d t heref ore m o bile visit s ca n n ot be or ga nize d, st u d y  
treat m e nt m ust be di sc o nt i n ue d earl y a n d d osi n g decisi o ns f o r t he al ter nat i ve treat me nt are 
all o we d t o be perf or me d b y tele p h o ne. 
St u d y  s u p plies f or bl o o d gl uc ose m o nit ori n g as well as alter nati ve treat me nts will be pr o vi de d t o 
t h e partici pa nt u nt il t he e n d of t he safet y f o ll o w- u p peri o d ( 6 wee ks after t he last d ose of 
L Y 3 2 0 9 5 9 0 or 5 wee ks after t he last d ose of i ns uli n de gl u dec). If circ u msta nces per mit ,eff orts 
ma y be ma d e t o o btai n a n i m m u n o ge nicit y bl o o d sa m ple after t his f oll o w -u p. After t he e n d of 
t h e safet y f o ll o w-u p peri o d, st u d y  s u p plies ha ve t o be ret ur ne d or dis p ose d as directe d b y  t h e 
st u d y  t e a m .
P arti ci p a nt s ha ve t o c o nti n ue t o e nter t heir bl o o d gl uc ose, h y p o gl yce mia a n d i ns uli n d ose 
i nf or m at i o n i nt o t hei r el e ctr o ni c diari es t o gi ve t he i n vesti gat i ve site c o nt i n ue d re m ote access t o 
t h ese data.  After ter mi nati o n o f st u d y  tr e at m e nt ,L Y 3 2 0 9 5 9 0 /i ns uli n de gl u d ec s h o ul d be 
r e pl ace d b y t he pre vi o usl y use d basal i ns uli n.  
 
  T heref ore, a sl o w u p -ti tr ati o n 
of  a n ot her basal i ns uli n is necessar y  t o pre ve nt h y p o gl yce mia d ue t o o verla p pi n g i ns uli n act i o n
af ter t he di sc o nt i n uat i o n of L Y 3 2 0 9 5 9 0 . D uri n g t his re m ote u p -ti tr ati o n , n o i ns uli n s h o ul d be 
d ose d u ntil t he st u d y parti ci pa nt’s me d ia n fast i n g gl uc ose o ver a n y  7 -da y peri o d i ncreases t o 
> 1 20 m g/ d L, a n d t he n dail y basal i ns uli n w o ul d be i nit iate d a n d a dj uste d base d o n fa sti n g 
gl uc ose .St u d y  p arti ci pa nts assi g ne d t o t he i ns uli n de gl u dec treat me nt gr o u p will s witc h t o t he 
basal i ns uli n use d bef ore e nteri n g t he st u d y . If i ns uli n de gl u dec was t he pre -st u d y  basal i ns uli n, 
t h e y  ca n c o nti n ue wi t h  t he sa me d ose use d u ntil t he st u d y i nt er ve nt i o ndisc o nt i n uat i o n.  If  t h e y  
s wi tc h t o a n ot her basal i ns uli n (e. g., i ns uli n glar gi ne), st u d y  p arti ci pa nts s h o ul d i nject a dail y 
d ose w hic h is 2 0 % l o wer t ha n t he last d ose of i ns uli n de gl u dec use d bef ore t h e st u d y  i nt er ve nti o n 
di sc o nti n uat i o na n d ti trate u n d er r e m ote s u per visi o n of t he i n vest i gat or usi n g t he c o u ntr y -C CI 
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 92specific label for their pre -study  basal insulin. In case remote visits are impossible ,the 
participant must be hospitalized for a safe transit ion to an al ternative ant idiabet ic treatment.
Replacement of Study Participants
The dropout rate will be monitored regularly during the study . If the dropout rate is over 15%
prior to com pletion of 12 weeks of treatment , addi tional participants may be enrolled to ensure 
approximately  190 partici pants complete 12 weeks of treatment.
Documentation
The sites mustident ify and docum ent the details o f how all pa rticipants and visit s were affected 
by the COVID -19 pandemic restrict ions.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 9310.11. Appendix 11: Abbreviations
Term Definition
ADA anti-drug antibodies
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
participant administered a pharmaceutical product that does not necessarily have a 
causal relationship with this treatment.  An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a medicinal (investigational) product, 
whether o r not related to the medicinal (investigational) product.
AESI adverse events of special interest
ALT alanine aminotransferase
AST aspartate aminotransferase
BG blood glucose
blinding/masking A single -
blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participant are not.
A dou ble-blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the 
participants are aware of the treatment received.
BMI body mass index
BP blood pressure
CGM continuous glucose monitoring
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
Com panion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performan ce of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CONSORT Consolidated Standards of Reporting Trials
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 94CV cardiovascular
DKA diabetic ketoacidosis
DMC data monitoring committee
DNA deoxyribonucleic acid
EAS efficacy analyses set
ECG electrocardiogram
ED early  discontinuation
EDC electronic data capture system
eDiary electronic diary
eGFR estimated glomerular filtration rate
ELISA enzyme-linked immunosorbent assay
enroll The act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB ethical review board
ET Early  termination
FFA free fatty acids
FG fasting glucose
GCP good clinical practice
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonization
IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study  
that are relevant to the participant’s decision to participate.  Informed consent is 
documented by means of a written, signed and dated informed consent form.
INR internatio nal no rmalized ratio
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 95interim analysis An interim analysis is an analys is of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IP: investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further i nformation about the authorized form.
IRB/IEC Institutio nal Review Boards/Independent Ethics Committees
ISR injection site reaction
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant ( i.e., the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analy zed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS interactive web -response sy stem
MAD multiple -ascending dose
MDI multiple daily injections
MMRM mixed-effect model for repeated measurements
NAFLD non-alcoholic fatty liver disease
NIM non-inferio rity margin
NIMP Non-investigational Medicinal Product
OTC over the counter
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PC product complaint
PK/PD pharmacokinetics/pharmacodynamics
PPS per-protocol set:  The set of data generated by the subset of participant who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
QTc corrected QT interval
SAD single -ascending dose
SAE serious adverse eve nt
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 96SAP statistical analysis plan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SMBG self-monitoring blood glucose
SOA schedule of activities
SUSARs suspected unexpected serious adverse reactions
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal re lationship 
with this treatment.
TE treatment -emergent
ULN upper limit of normal
UK United Kingdom
US United States
WOCBP woman of childbearing potential
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 9710.12. Appendix 12: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment [c]: 14 A ugust 2020
This amendment is consi dered substant ialbased on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
The am endment provi des informat ion to reflect and reinforce invest igational medical device 
requi rements absent in the init ial study  protocol  for Al gorithm 2.  These requi rements are 
consis tent wi th country  regul ations where Algorithm 2 will be used.
Section # and Name Description of Change Brief Rationale
Section 1.1. Synopsis
Section 1.2. Schema
Section 4.1.1. Study Visits
Section 6.1. Study 
Interventions(s) AdministeredAddition of language regarding 
randomizationClarify  that randomization distribution may 
vary based on country due to removal of 
randomization into LY3209590 Algorithm 2 
(digital) treatment for the European Union 
(EU)
Section 1.3 Schedule of 
ActivitiesAddition of product complaint 
review in AE/SAE reviewProduct complaint review was added to 
ensure alignment with Lilly guidance
Section 2.3. Benefit/Risk 
AssessmentAddition of language related to 
LY3209590 Algorithm 1 
(paper) and LY3209590 
Algorithm 2 (digital)Addi tions to clarify regulatory designation of 
LY3209590 Algorithm 1 (paper) and 
LY3209590 Algorithm 2 (digital)
Section 2.3.1. Protocol Risk 
Mitigation F eatures for 
Investigational Algorithm 2Addition of language for 
protocol risk mitigation Summarization of key risk mitigations for the 
protocol including investigational medical 
device
Section 4.1.1. Study Visits Updated wording describing 
Algorithm 2Clarification of Algorithm 2 as an 
investigational individualized accruing data 
algorithm
Section 6.1. S tudy 
Interventions(s) AdministeredAddition of language describing 
Algorithm 1 and Algorithm 2Clarification and description of algorithms 
Section 6.1.2.3. Management 
of Patients with Severe, 
Persistent Hyperglycemia 
during Treatment PeriodAddition of language related to 
transient hyperglycemiaProvide acknowledgment of the potential for 
trans ient hyperglycemia and guidance for 
management during transition period from 
prestudy  basal to LY3209590
Section 6.1.3. Medical 
DevicesAddition of language for 
Algorithm 2Algorithm 2 was added based on regulatory 
feedback and classification as a medical 
device
Section 6.2. 
Preparation/Handling/Storage/
AccountabilityAddition of language for 
accountability and accessDescriptio n of labeling and appropriate 
access controls by authorized trained 
personnel to meet regulatory requirements
Section 8.3.8. Product 
ComplaintsAddition of required section Product complaint section added to align 
with Lilly  template and guidance
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 98Section # and Name Description of Change Brief Rationale
Section 9. Statistical 
ConsiderationsClarifications throughout Clarifications and corrections provided to 
ensure consistency with the statistical 
analy sis plan
Section 9.2 Sample Size 
DeterminationsRevised language related to 
statistical power Language added to reflect the change in 
statis tical power resulting from removal of 
Algorithm 2 from  the EU
Section 10.1.1. Regulatory 
and Ethical ConsiderationsAddition of language related to 
emergency circumstancesClarification of guidance during emergency 
circumstances requiring prior approval of 
Lilly  for regulatory  compliance
Section 10.3.3. Definition of 
an Unanticipated Adverse 
Device Effect (UADE)Addition of section related to 
unanticipated adverse device 
effect (UADE)Guidance on definitions and procedures for 
handling UADEs
Section 10.8.1. LY3209590 
Algorithm 1 (paper algorithm)Addition of language for 
investigatorsClarified guidance for investigators 
contacting Lilly Medical to be consistent 
with guidance provided for Algorithm 2
Section 10.8.2 LY3209590 
Algorithm 2 (digital 
algorithm)Addition of language related to 
dosing and input of data for 
Algorithm 2Clarification for investigators on the use of 
Algorithm 2
Throughout Minor editorial and document 
formatting revisionsThese are minor changes; therefore, they 
have not been s ummarized
Amendment [b]: 12 Jun e 2020
This amendment is consi dered substant ialbased on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
This provides guidance if COVID -19 rel ated l ocal restri ctions impact the participant’s abilit y to 
attend thei r onsi te study  visits as ori ginally scheduled.
Section # and 
NameDescription of Change Brief Rationale
Section 10.10 
Appendix 10Added Appendix 1 0: Changes to Study 
Procedures due to the COVID -19 
Pandemic or Natural DisastersMitigation if COVID -19 related restrictions 
make it impossible for the participant to travel to 
sites for originally scheduled visits.
Amendment [a]: 08 Apr il 2020
This amendment is consi dered substant ialbased on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
This amendment addresses Food and Drug Administration (FDA) feedback.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 99Section # and Name Description of Change Brief Rationale
1.3. Schedule of 
ActivitiesMoved text from under ‘Notes’ for the 12 -
lead ECG to footnote dTo include all information relevant to 
the ECG assessment under one 
footno te
1.3. Schedule of 
ActivitiesUpdated text specifying PK sample 
collection in participants randomized to 
LY3209590To better reflect that PK samples 
were only  collected for participants 
randomized to the LY3209590 group
1.3. Schedule of 
ActivitiesAdded text regarding the assessment of 
C-peptide under ‘Notes’ sectionTo better reflect the assessment of C -
peptide during screening and lead -in
1.3. Schedule of 
ActivitiesAdded ‘X’ at Visit 3 for the procedure 
‘Review diary data and make dose 
individualizat ion assessment’Corrected an error:  initial dose 
selection based on the diary entries 
between V2 and V3 has to be done at 
V3
1.3. Schedule of 
ActivitiesUpdated footnotes d and e to accommodate 
the language in the notes section for the 12 -
lead ECG and to indicate that PK samples 
were not to be collected for participants in 
the insulin degludec treatment groupTo streamline presentation of all 
relevant information under the 
footnotes and to better reflect that PK 
samples were only collected for 
participant s randomized to the 
LY3209590 group
1.3. Schedule of 
ActivitiesAdded footnote f to ‘Study participant CGM 
training’ to specify that the patients will be 
fitted with Dexcom G6® for CGM 
monitoringPer regulatory feedback
3. Objectives Deleted ‘recurrence’ for hypoglycemic 
events from the endpoints for the 
tertiary /exploratory objective of exploring 
the quality of glycemic control of 
LY3209590 compared with insulin degludec 
using CGMCorrection of an error
4.1.1. Study Visits,
5.1. Inclusion Criteria,
8.2.4.Self-monitoring 
of Blood Glucose 
(SMBG)Included the CGM system name ‘Dexcom 
G6’Per regulatory feedback
4.3. Justification for 
DoseDeleted ‘after consultation with Lilly 
Medical’ in the statement regarding dose 
alteratio ns recommended by dose 
adjustm ents algorithms, under the discretion 
of investigators.  Added text regarding 
documentation required in case of deviation 
from the algorithm -recommended doseCorrected an error:  prior consultation 
with Lilly  Medical is not required for 
the investigator fo r dose alteratio ns of 
LY3209590
5.1. Inclusion Criteria Added that C-peptide needs to be assessed to 
be ≤0.30 nmol/L at screening or before 
randomizationTo clarify that an additional C -peptide 
evaluation can also be performed, if 
required, at Visit 2, be fore 
randomization
5.1. Inclusion Criteria Changed ‘insulin levemir’ to ‘insulin 
detemir’ in inclusion criterion 6 in the current 
protocolFor consistency with using the 
generic name
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 100Section # and Name Description of Change Brief Rationale
5.1. Inclusion Criteria Added the lower threshold of 5.6% to the 
HbA1c range for inclusion in the studyPer regulatory feedback
5.1. Inclusion Criteria Added text to specify the dosing regimen of 
insulin prior to screeningPer regulatory feedback
5.2. Exclusion Criteria Updated the exclusion criteria to explicitly 
exclude w omen of childbearing potential 
who are not using adequate contraception, 
pregnant women, women intending to 
become pregnant, or lactating womenPer regulatory feedback
5.2. Exclusion Criteria Updated the exclusion criterion regarding 
glucocorticoid use (e xclusion criterion 29 in 
the current protocol) to correct the duration 
of sy stemic therapy to be considered chronic 
to 14 days. This is consistent with Section 
6.5.2Corrected text to be consistent with 
Section 6.5.2
5.2. Exclusion Criteria Updated exclusion criteria numbering due to 
the addition of the exclusion criteria per 
regulato ry feedbackUpdate in formatting
6.1.2.1. Standards of 
Medical CareAdded the statement, “Standards of 
prevention of persistent hyperglycemia and 
ketone monitoring must be followed during 
the course of the study to prevent DKA”Per regulatory feedback, to further 
clarify  the steps/mitigate the risk of 
hyperglycemia and DKA when 
starting LY3209590 or transitioning 
to other therapies (at the end of the 
trial)
6.1.2.2. Man agement of 
Increased 
Hypoglycemia RiskReplaced ‘confirmed’ with ‘documented’ 
hypoglycemia from the definition of 
increased risk of hypoglycemia
Added the definition of documented 
hypoglycemiaPer regulatory feedback
6.4 Study Intervention 
ComplianceUpda ted text regarding IP accountability To better reflect the process for IP 
accountability
7.1.1 Permanent 
Discontinuation from 
Study TreatmentAdded text for discontinuation from 
following occurrence of a systemic 
hypersensitivity reactionTo clarify better the circumstances 
under which participants will be 
discontinued from the IP
8.3.7.1 Hypoglycemia Deleted ‘ED2’ as one of the last visits ED2 is not necessarily the last study 
visit if patient continues the study 
without IP
8.3.7.1. Hypoglycemia Amended text regarding the reporting of 
hypoglycemiaTo clarify how information regarding 
hypoglycemia is to be collected
8.3.7.1. Hypoglycemia Deleted text describing the thresholds for 
analy sis.These thresholds will be used for 
analy ses, and do not need to be 
included in the protocol.  The 
thresholds for algorithms are updated 
in Section 10.8.1.
8.3.7.3. Systemic 
Hypersensitivity 
ReactionsAdded a section on systemic hypersensitivity 
as adverse events of special interestTo update the protocol with syste mic 
hypersensitivity as an adverse event 
of special interest
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 101Section # and Name Description of Change Brief Rationale
8.4. Treatment of 
OverdoseUpdated the text to provide guidance 
regarding the management of overdose with 
LY3209590Per regulatory feedback
8.5. Pharmacokinetics Updated the text to clarify that PK samples 
were not to be collected for participants 
randomized to insulin degludecTo better reflect that PK samples 
were only  collected for participants 
randomized to the LY3209590 group
9.3. Populations for 
Analy sesUpdated the description of the 
pharmacokinetic population to indicate that 
these participants have at least 1 evaluable 
PK sampleTo clarify better the inclusion pf 
patients in the pharmacokinetic 
populatio n
9.4.6.3. Hypoglycemia 
EpisodesAmended text to clarify that hypoglycemia 
will be analyzed according to the definitions 
in the American Diabetes Association 
classification systemTo explain the analysis of 
hypoglycemia
10.1.6. Data Quality 
AssuranceReplaced ‘captured’ with ‘entered by patient’ 
to clarify  that hy poglycemic events wi ll be 
entered by patients in the eCOATo clarify the text regarding data 
collection for hypoglycemic events
10.2.
Appendix 2Updated the text to clarify that the 
investigators must document their review of 
each laboratory safety report and updated the 
footnotesTo correct errors, add information, 
and improve readability
10.8.1.
Appendix 8Updated the text regarding the LY3209590 
algorithm 1 (paper algorithm)Per regulatory feedback
10.9. Appendix 9 Added an appendix to describe recommended 
laborato ry testing for hypersensitivity eventsTo update the protocol with systemic 
hypersensitivity as an adverse event 
of special interest
Throughout the protocol Minor editorial and formatting changes Minor, therefore not described
Abbreviations:  ECG =electrocardiogram; eCOA =electronic Clinical Outcome Assessment ; ED2 (visit) =Early  
Discontinuation 2 (visit); IP =investigational product; PK =pharmacokinetic.
CONFIDENTIAL I8H-MC-BDCP (d)
LY3209590 10211. References
[ADA] American Diabetes Associat ion. Standards of medical care in diabetes—2016. Diabetes 
Care . 2016;39(suppl 1):S4
-S108.
[ADA] American Diabetes Associat ion. Standards of medical care in diabetes—2019. Diabetes 
Care . 201 9;42(suppl  1):S4 -S193.
[FDA] Food and Drug Administration. Guidance for Industry . Diabetes Mellitus:  Developing 
Drugs and Therapeut ic Biologics for Treatment and Prevent ion. 2008. Available at:
https://www.fda.gov/media/71289/download . Accessed: December 3, 2019.
Heise T, Nosek L, B øttcher SG, Hastrup H, Haahr H. Ult ra-long-acting insulin deglud ec has a 
flat and stable glucose -lowering effect in ty pe 2 diabetes. Diabetes Obes Metab . 
2012;14(10):944-950.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR. Management of Hy perglycemia in Type 2 Di abetes, 2015: A 
Patient-Centered Approach: Update to a Posit ion Statement of the American Diabetes 
Associ ation and the European Associat ion for the Study  of Diabetes. Diabetes Care . 
2015; 38(1):140 - 149.
[NDA] National Diabetes Audit. National Diab etes Audit Report: 1 Care Processes and 
Treatment Targets 2016 -17. Available at: https://digital.nhs.uk/data- and-
inform ation/publicat ions/stati stical/nat ional-diabetes -audit/national-diabetes -audit-report -1-
care-processes -and-treatm ent-targets -
2016 -17. Published 10 November 2017.  Accessed :
November 1, 2019.  
Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study  Investi gators. The Treat -to-
Target Trial: Rando mized addit ion of glargine or hum an NPH insulin to oral therapy  of type 2 
diabetic pat ients. Diabetes Care . 2003;26:3080 –3086.
Strange P. Treat -to-target insulin titration algorithms when init iating long or intermediate acting 
insulin in t ype 2 diabetes. J Diabetes Sci Technol. 2007;1(4):540 -
548.
Tresiba® prescribing informat ion [USPI 2015]. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf . Accessed :January  
11, 2018.
L e o  D o c u m e n t  I D  =  8 f 5 2 b c 1 3 - 7 c 8 6 - 4 b 9 6 - b 7 f 0 - 8 f 2 a 2 5 c c a 0 4 8 
A p p r o v e r : 
A p p r o v a l  D a t e  &  T i m e :  2 8 - O c t - 2 0 2 0  1 4 : 3 3 : 5 1  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r : 
A p p r o v a l  D a t e  &  T i m e :  2 8 - O c t - 2 0 2 0  1 5 : 3 7 : 5 2  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 